



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Effectiveness of interventions for dementia in low- and middle-income countries: Protocol for a systematic review, pairwise and network meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027851
Article Type:	Protocol
Date Submitted by the Author:	12-Nov-2018
Complete List of Authors:	Salcher-Konrad, Maximilian; London School of Economics and Political Science, Personal Social Services Research Unit (PSSRU) Naci, Huseyin; London School of Economics and Political Science, Health Policy McDaid, David ; London School of Economics and Political Science, Personal Social Services Research Unit (PSSRU) Alladi, Suvarna; NIMHANS, Bangalore, India Oliveira, Deborah; Federal University of Sao Paulo (UNIFESP); University of Nottingham Institute of Mental Health Fry, Andra; London School of Economics and Political Science, Library Hussein, Shereen; University of Kent, Personal Social Services Research Unit (PSSRU) Knapp, Martin; London School of Economics and Political Science, Personal Social Services Research Unit (PSSRU) MUSYIMI, CHRISTINE; AFRICA MENTAL HEALTH FOUNDATION, RESEARCH Ndeti, David; Africa Mental Health Foundation; University of Nairobi Lopez-Ortega, Mariana; National Institute of Geriatrics, National Institutes of Health Comas-Herrera, Adelina; London School of Economics and Political Science, Personal Social Services Research Unit (PSSRU)
Keywords:	Dementia < NEUROLOGY, low and middle income countries, developing countries, alzheimer disease, lamics, systematic review

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Effectiveness of interventions for dementia in low- and middle-income countries: Protocol for a systematic review, pairwise and network meta-analysis

Maximilian Salcher-Konrad ^{*,1}, Huseyin Naci ², David McDaid ¹, Suvarna Alladi ³, Déborah Oliveira ^{4,5}, Andra Fry ⁶, Shereen Hussein ⁷, Martin Knapp ¹, Christine Musyimi ⁸, David M. Ndeti ^{8,9}, Mariana Lopez Ortega ¹⁰, Adelina Comas-Herrera ¹

* Corresponding author.
Address: PSSRU, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, United Kingdom.
Email: m.salcher@lse.ac.uk
Telephone: +44 (0) 20 7955 6959
¹ Personal Social Services Research Unit (PSSRU), London School of Economics and Political Science, London, United Kingdom.
² Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.
³ National Institute of Mental Health and Neuro Sciences, Bangalore, India.
⁴ Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil.
⁵ Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom.
⁶ Library, London School of Economics and Political Science, London, United Kingdom.
⁷ Personal Social Services Research Unit (PSSRU), University of Kent, Canterbury, United Kingdom.
⁸ Africa Mental Health Foundation, Nairobi, Kenya.
⁹ University of Nairobi, Nairobi, Kenya.
¹⁰ National Institute of Geriatrics, National Institutes of Health, Mexico City, Mexico.

Word count, excluding title page, abstract, references, figures and tables: 4,384

ABSTRACT

Introduction: There are more people living with dementia in low- and middle-income countries (LMICs) than in high-income countries. Evidence-based interventions to improve the lives of people living with dementia and their carers are needed, but a systematic mapping of methodologically robust studies in LMICs and synthesis of the effectiveness of dementia interventions in these settings is missing.

Methods and analysis: A systematic review and meta-analysis will be conducted to answer the question: Which dementia interventions were shown to be effective in LMICs and how do they compare to each other? Electronic database searches (MEDLINE, EMBASE, PsycINFO, CINAHL plus, Global Health, WHO Global Index Medicus, Virtual Health Library, Cochrane CENTRAL, Social Care Online, BASE, MODEM toolkit, Cochrane Database of Systematic Reviews) will be complemented by hand searching of reference lists and local knowledge of existing studies from an international network of researchers in dementia from LMICs. Studies will be eligible for inclusion if they were published between 2008 and 2018, conducted in LMICs and evaluated the effectiveness of a dementia intervention using a study design that aims to establish a causal treatment effect. In addition to narrative synthesis of the interventions, feasibility of pairwise and network meta-analyses will be explored to obtain pooled effects of relative treatment effects.

Ethics and dissemination: Secondary analysis of published studies, therefore no ethics approval required. Planned dissemination channels include a peer-reviewed publication as well as a website, DVD and evidence summaries.

Registration details: PROSPERO CRD42018106206 (www.crd.york.ac.uk/prosperto)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STRENGTHS AND LIMITATIONS OF THE STUDY

- This protocol defines the scope, inclusion/exclusion criteria, and analytical approach for the first comprehensive assessment of methodologically robust dementia intervention studies in low- and middle-income countries (LMICs), the setting where most people with dementia currently live.
- Eligible study designs include both randomised trials and non-randomised studies capable of establishing causality, with stringent eligibility criteria applied for the latter.
- Planned analyses include a narrative synthesis mapping out the interventions studied in LMICs as well as traditional pairwise and network meta-analysis, capable of yielding relative treatment effect estimates for interventions that have been compared either directly or indirectly (through a common comparator) to each other.
- A low number of studies may be eligible for inclusion, potentially limiting the scope for quantitative meta-analysis.

INTRODUCTION

More people with dementia are now living in low- and middle income countries (LMICs) compared to high-income countries.[1] Dementia is described by the Alzheimer's Association as "an overall term that describes a group of symptoms associated with a decline in memory or other thinking skills severe enough to reduce a person's ability to perform everyday activities." [2]. Like other mental disorders, it places a significant burden on societies in LMICs, where care is often provided by family members and/or financed out-of-pocket, magnifying its impact beyond the individual living with the condition.[3] While no curative treatment for dementia exists, a range of interventions aimed at improving the lives of people living with dementia and their carers have been developed and progress made in evaluating and understanding which of these are effective.[4] Despite the large and increasing burden of dementia in LMICs, these interventions have been primarily evaluated in high-income settings. Better understanding of the impact of dementia in LMICs and how people living with the disease can be better supported are therefore considered to be a priority.[5] Building capacity for research and policy-making is at the heart of the recently launched STRiDE project (www.stride-dementia.org), as part of which a systematic review of the effectiveness of dementia interventions in LMICs will be conducted.

Research on dementia and dementia-related interventions, many aiming to improve the quality of life of those who are affected by the condition and their carers, has increased considerably since it was recognised as a key challenge for care systems: in mid-2018, the Cochrane Database of Systematic Review (www.cochranelibrary.com) listed over 120 systematic reviews of dementia-related interventions carried out since 2000 by their Dementia and Cognitive Improvement Group. Evidence on effectiveness and cost-effectiveness of a variety of dementia interventions has been recently summarised by other groups, prime among them the MODEM project.[6] A comprehensive database of over 1,400 dementia intervention studies, along with a toolkit containing evidence summaries for decision-makers, people living with dementia and their carers was created (<http://toolkit.modem-dementia.org.uk/>).

The increase in knowledge about disease aetiology, prevention and management is expected to contribute to better quality of life for people living with dementia and their carers through the implementation of evidence-based approaches to diagnosing, managing and enhancing quality of life while living with the disease. The World Health Organization,[5] organisations

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

representing people living with dementia and their families,[7] and researchers [4] are all calling for decision-makers to focus on such approaches when developing policies and programmes. Evidence-based practices are informed by studies with strong research designs capable of establishing a causal link between an intervention (be it a drug, non-pharmacological therapy, organisational change, or another form of intervention) and improved outcomes in people living with dementia and their carers. While randomised controlled trials (RCTs) are considered the ‘gold standard’ of intervention studies, other study designs exist that allow researchers to draw causal conclusions about the effect of an intervention in the absence of RCTs and can provide essential evidence on ‘what works’.[8,9]

Interventions with proven positive impacts in high-income countries have previously been summarised in the MODEM dementia evidence toolkit. However, it is unclear whether interventions that showed beneficial effects in high-income settings, such as cognitive stimulation therapy for cognition and quality of life,[10,11] advance care planning,[12] training for formal carers (such as STAR)[13] and support for family carers (START),[14] are also effective in less-resourced settings, where awareness about dementia is lacking and dementia care may not be a policy priority. In this context, dementia is reported to be under-diagnosed and specialised care is often not available,[7] raising the question of which dementia interventions work in LMICs. The aim of this systematic review is to help fill this research gap by identifying dementia interventions for which robust evidence on effectiveness in LMICs exists and to synthesise available evidence to determine which interventions have the most potential of achieving desired outcomes in these settings.

METHODS AND ANALYSIS

This systematic review and meta-analysis protocol adheres to the PRISMA-P checklist [15] and was registered on the PROSPERO platform (www.crd.york.ac.uk/prospero): CRD42018106206.

Review question

Which dementia interventions have been shown to be effective in low- and middle-income countries and how do they compare to each other?

Inclusion criteria

Population

We will include studies that have evaluated the effectiveness of an intervention in adults (18 years and over) living with dementia or their carers.

We will include studies in all stages (including early- to late-stage dementia) and different forms of dementia (e.g., Alzheimer's disease, vascular dementia, Lewy bodies dementia, and mixed dementias, as well as less common forms such as fronto-temporal dementia). We will also be mindful of risks of dementia associated with conditions such as HIV/AIDS that may be more prevalent in LMICs. Due to the particularly high risk of people with mild cognitive impairment (MCI) developing dementia (approximately one third will develop dementia over a period of three to ten years),^[16] we will also include studies focusing on this group.

Carers of people living with dementia include family members, other unpaid carers, as well as professional carers, irrespective of whether or not they are paid, and whether or not they are living with the person they care for.

Studies will be included if they were conducted in a country considered a LMIC according to the OECD categorisation at any time during the study period. The lists of aid recipient countries for the years 2008-2018 were used to identify LMICs

(<http://www.oecd.org/development/financing-sustainable-development/development-finance-standards/historyofdaclistsofaidrecipientcountries.htm>).

We will include studies that were conducted entirely in LMICs, or (in the case of multi-country studies) where 50% or more of study participants received the intervention of interest in LMICs or where results were presented separately for participants in LMICs.

Intervention

One of the aims of this systematic review is to identify which interventions have been rigorously evaluated in LMICs. The eligibility criteria for types of interventions are therefore deliberately kept open: we will include all interventions that aim to improve the lives of people living with dementia and their carers contingent on the intervention having been subjected to a rigorous evaluation (see eligible study designs below). We will apply an 'effectiveness' perspective with respect to interventions, i.e. interventions are eligible when defined as such

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

in a study and improved outcomes are expected through the intervention.[17] We will focus on people already living with dementia and their carers and will therefore exclude primary prevention studies.

Dementia interventions can vary in terms of who they are targeting (person living with dementia; unpaid carers; care professionals and care systems); what the aim of the intervention is (secondary prevention; treatment; disease management; coping with caring for people living with dementia; managing the impact of dementia on the care system); and their mechanism (including diagnosis; pharmacological treatment; cognitive therapy; technological interventions; training; exercise; sleep therapy; music therapy; organisation of care, including advance care directives and case management; support for carers; financing of care; policy interventions; and others).[4]

Comparison

All comparisons will be eligible, including active comparators, usual practice/standard care/placebo and no action.

Outcomes

Outcomes of dementia intervention studies are highly heterogeneous and may vary by who is affected (person living with dementia; their carer(s); wider society and care system) and type of outcome (clinical outcomes, such as cognitive, neurological, psychological, psycho-social; quality of life and functioning outcomes; care and delivery of care, such as the use of feeding tubes, hospitalisations, institutionalisations; economic outcomes; diagnosis rates; knowledge of the disease and ability to cope with caring for people with dementia). For example, recommendations on dementia interventions were recently made based on a review of the evidence on outcomes in domains ranging from, among others, cognition and neuropsychiatric outcomes to end-of-life care and care delivery.[4]

Given the broad range of potentially relevant outcomes, a search strategy that captures all of these is not feasible. Restricting inclusion criteria to certain types of outcomes would risk excluding potentially important parts of the evidence base for dementia interventions in LMICs. The impact of dementia is recognised to be experienced by different people and at different levels, including by people living with dementia, their carers, communities and the

care system and wider society,[18] and interventions therefore need to take all of these perspectives into account.[5]

Study design

The research question we aim to answer is what works in dementia in LMICs. We are therefore interested in the effect that an intervention had on outcomes in people receiving the intervention, their carers and the wider care system.[19] Accordingly, we will apply a causal inference framework in this review: study designs eligible for inclusion are those that allow researchers to establish a causal link between the intervention and observed outcomes. This includes experimental designs (RCTs and cluster-RCTs) as well as non-randomised designs suitable for causal inference, defined as “comparisons of ‘potential outcomes’ [...] under different treatment conditions on a common set of units.”[8] We will include both randomised and non-randomised studies due to an anticipated low number of well-conducted randomised trials in LMICs, based on previous work (searches conducted for the MODEM evidence toolkit, and a previous review on packages of care for people living with dementia in LMICs [20]). Also, non-randomised studies may have greater generalisability beyond the studied environment when conducted in settings and populations closer resembling routine practice.

In order to maximise the number of eligible studies and synthesise as much robust evidence about dementia interventions in LMICs as possible, we will extend the eligibility criteria used by the Cochrane Effective Practice and Organisation of Care (EPoC) Group [21] to also include other quasi-experimental study designs in addition to those typically seen in methodologically robust evaluation studies (non-randomised controlled trials, controlled before-after studies, and interrupted time series studies). The label ‘quasi-experimental’ is discipline-specific and members of the Cochrane Non-Randomized Studies for Interventions Methods Group therefore developed a ‘label-free’ taxonomy of quasi-experimental studies that aims to define such studies through a series of questions in six domains.[22] We will use their checklist to guide the selection of studies by study design (see Table 1). Since we anticipate a shortage of methodologically robust studies of dementia interventions in LMICs, but still aim to synthesise the best available evidence that provides causal treatment effects, we adapted the original checklist by removing restrictions to answer ‘yes’ to only one question in domains 2, 3, and 4. This will enable us to include several strong experimental and quasi-experimental study designs, including RCTs (including cluster-RCTs); non-randomised controlled trials; controlled before-after studies; interrupted time series studies; difference-in-differences

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

studies; instrumental variables studies; regression discontinuity design studies; and other study designs that employ methods such as propensity score matching that attempt to control for observed and unobserved confounders.

As a contingency plan in case no such studies can be identified in LMICs, we define a secondary set of inclusion criteria to still capture intervention studies in LMICs with less robust designs but that could still inform our understanding of what works in dementia in LMICs in the absence of better study designs. The secondary set of inclusion criteria will mirror the primary inclusion criteria, with the exception of study design. In the secondary set of inclusion criteria, studies will also be eligible for inclusion if they control only for observed confounders (criterion 4 in Table 1).

TABLE 1: CHECKLIST FOR ELIGIBLE STUDY DESIGNS (BASED ON REEVES ET AL.[22])

Feature	Eligible for inclusion if...
1. Was the intervention/comparator:	
Allocated to (provided for/administered to/chosen by) individuals?	Yes
Allocated to (provided for/administered to/chosen by) clusters of individuals?	Yes
Clustered in the way it was provided (by practitioner or organizational unit)?	Yes
2. Were outcome data available:	
After intervention/comparator only (same individuals)?	No
After intervention/comparator only (not all same individuals)?	No
Before (once) AND after intervention/comparator (same individuals)?	Yes
Before (once) AND after intervention/comparator (not all same individuals)?	Yes
Multiple times before AND multiple times after intervention/comparator (same individuals)?	Yes
Multiple times before AND multiple times after intervention/comparator (not all same individuals)?	Yes
3. Was the intervention effect estimated by:	
Change over time (same individuals at different time points)?	Yes
Change over time (not all same individuals at different time points)?	Yes

Difference between groups (of individuals or clusters receiving either intervention or comparator)?	Yes
4. Did the researchers aim to control for confounding (design or analysis)	
Using methods that control in principle for any confounding?	Yes
Using methods that control in principle for time-invariant unobserved confounding?	Yes
Using methods that control only for confounding by observed covariates?	No
5. Were groups of individuals or clusters formed by	
Randomisation?	Yes
Quasi-randomisation?	Yes
Explicit rule for allocation based on a threshold for a variable measured on a continuous or ordinal scale or boundary (in conjunction with identifying the variable dimension, below)?	Yes
Some other action of researchers?	Yes
Time differences?	Yes
Location differences?	Yes
Health care decision makers/practitioners?	Yes
Participants' preferences?	Yes
Policy maker?	Yes
On the basis of outcome?	No
Some other process? (specify)	-
6. Were the following features of the study carried out after the study was designed	
Characterisation of individuals/clusters before intervention?	Yes
Actions/choices leading to an individual/cluster becoming a member of a group?	Yes
Assessment of outcomes?	Yes
7. Were the following variables measured before intervention:	
Potential confounders?	Yes
Outcome variable(s)?	Yes

Publication type

We will include peer-reviewed journal articles, including primary publications of intervention studies and systematic reviews of these, and grey literature describing evaluations of dementia interventions in LMICs (e.g., PhD theses and reports published by care system administrative bodies and non-governmental organisations). Systematic reviews are only eligible for inclusion

if their focus is on LMICs (i.e., if LMICs were specified as geographical setting in their inclusion criteria) and we will use these to identify primary studies eligible for inclusion (eligible if 50% or more participants were in LMICs or results were reported separately for LMIC settings). We will also include conference abstracts, provided they contain information to assess eligibility for inclusion.

BOX 1: EXCLUSION CRITERIA

We will exclude studies meeting any of the following conditions:

- Studies where less than 50% of participants received the intervention of interest in LMICs or where no results are available for a LMIC sub group
- Studies where no clear intervention was described
- Studies of associations between exposure and outcome (as opposed to causal links between intervention and outcome)
- Studies of primary prevention of dementia
- Studies where reports are not available in a language spoken by the international project team members (languages spoken include Arabic, English, French, German, Bahasa Indonesia, Portuguese, Romanian, Spanish, and Turkish)
- Studies that do not attempt to control for unobserved confounding, including cohort studies, case-control studies, cross-sectional studies, and case series (unless these have applied methods to control for unobserved confounders)
- Narrative reviews; overview articles; editorials; commentaries; letters to the editor
- Studies where animals (as opposed to humans) received the intervention

In case no studies meeting our primary inclusion criteria for study design can be identified, we will apply secondary inclusion criteria as specified under “Study design” and will amend the exclusion criteria for study design accordingly.

Search strategy

We will conduct searches in bibliographic databases (Box 2), using text words, subject headings and other search functions that each database offers. We will limit the searches to studies published from 2008 to 2018 and, where possible, will use filters to exclude editorials, commentaries, and letters to the editor, as well as running a search filter for animal studies.

BOX 2: ONLINE DATABASES TO BE SEARCHED

- MEDLINE (via OVID)
- EMBASE (via OVID)
- PsycINFO (via OVID)
- CINAHL plus (via EBSCO)
- Global Health (via CABI)
- WHO Global Index Medicus (GIM, includes databases from the six WHO regions: AIM (AFRO), LILACS (AMRO/PAHO), IMEMR (EMRO), IMSEAR (SEARO), WPRIM (WPRO))
- Cochrane CENTRAL and Cochrane Database of Systematic Reviews
- Social Care Online
- BASE
- Virtual Health Library

In addition to the international databases listed above, we will consider additional national or regional databases through consultation with STRiDE partners in seven LMICs (Brazil, India, Indonesia, Jamaica, Kenya, Mexico, South Africa). These databases might not be available in English and we will capitalise on the variety of languages spoken in the STRiDE consortium to include these in our search strategy, if deemed of sufficient added value for the identification of studies meeting our inclusion criteria.

We will also make use of previous efforts to systematically capture studies evaluating the effectiveness of dementia interventions and will review studies identified by other authors for inclusion. First, we will review studies included in the MODEM Dementia Evidence Toolkit (<http://toolkit.modem-dementia.org.uk>). The MODEM toolkit contains over 1,400 primary studies of dementia interventions. While the primary focus of the toolkit was on high-income settings, studies from LMICs may be included in the database. Secondly, we will screen existing Cochrane systematic reviews of dementia interventions for primary studies conducted in LMICs. We will review all Cochrane systematic reviews indexed in the Cochrane Library's dementia and cognition topic.

In addition to database searches, we will scan the reference lists of included studies to capture potentially missed ones. We will use Google Scholar, Scopus and Web of Science to carry out citation searches for the included papers.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

We will also capitalise on the expertise of STRiDE consortium partners (researchers and dementia advocacy groups) in seven LMICs (Brazil, India, Indonesia, Jamaica, Kenya, Mexico, South Africa) to include published and unpublished studies from these and other countries meeting our eligibility criteria if they were not captured by database searches.

We will further search trials registers (clinicaltrials.gov and the International Clinical Trials Registry Platform) to identify ongoing or planned clinical trials of dementia interventions in LMICs.

We will capitalise on the expertise of LSE’s information specialist support team to finalise the search strategy.

Search terms

Search terms were selected to reflect the key concepts making up the review question: dementia interventions that have been studied using robust research designs in LMICs. Exemplary search terms for MEDLINE via OVID for the concepts of population and intervention, study design, and LMICs are provided in Table 2, including the number of hits for each search as per 10th October 2018. The search for MEDLINE will be translated for the other databases.

The ‘intervention’ concept provided in Table 2 (lines 22-98) includes both generic terms as well as a range of specific interventions that have been studied for dementia before, although usually in high-income countries. We based the list of specific interventions on a thorough review of the evidence, conducted as part of the Lancet commission,[4] and through revision by the international STRiDE consortium. While this might not be a comprehensive list of all interventions that have ever been studied for dementia, we aimed to increase the likelihood of identifying relevant studies by combining generic search terms pertaining to interventions, therapies, etc. with specific intervention types and names of interventions, such as drug names.

We will use established study design and geographical location search filters to narrow down the number of results and will make adaptations as necessary to reflect our inclusion criteria. If such filters are not available for some databases, we will consider adapting the search filters used for MEDLINE.

The search filters for eligible study designs are provided in Table 2, rows 101-108 (for RCTs), 110-121 (for cluster-RCTs) and 123-147 (for other quasi-experimental studies), respectively. In order to identify RCTs, we will use the sensitivity-maximising version of the highly sensitive filter for RCTs recommended in the Cochrane Handbook.[23] For identification of cluster-RCTs, we will use the sensitivity-maximising filter for cluster-RCTs developed by Taljaard et al.[24] This filter was validated, among others, for a sample of cluster-RCTs in sub-Saharan Africa from before 2001 and showed good sensitivity (94%), with overall higher sensitivity for more recent studies. For identification of non-randomised studies that establish a causal relationship between exposure and outcome, we created an additional set of search terms pertaining to commonly used labels for quasi-experimental studies. We enhanced these search terms with the 'etiology' filter developed by the Hedges Group.[25] The methodological criteria used for developing the filter were found to be a good match for our inclusion criteria (including the use of a clearly identified comparison group, with examples given by the authors including "randomized controlled trials (RCT), quasi-randomized controlled trials, non-randomized controlled trials, cohort studies with case-by-case matching or statistical adjustment to create comparable groups, or nested case-control studies" [25]).

Finally, rows 149-157 of Table 2 show the exemplary search terms for LMICs, based on a filter for LMICs that is available from the Cochrane EPOC website (<http://epoc.cochrane.org/lmic-filters>). The search terms were expanded and updated to reflect the list of LMICs from 2008-2018.

Filters for LMICs and study designs were tested in MEDLINE for a sample of 10 studies (6 selected for being conducted in LMICs,[26-31] 4 selected for using quasi-experimental study designs [32-35]). The sensitivity of the search strategy for this sample was 100% (10/10 studies) for searches with study design filters, and 100% (6/6 studies) when adding the LMIC filter.

TABLE 2: EXEMPLARY SEARCH TERMS (MEDLINE VIA OVID)

Search #	Terms used	No. of hits
1	Exp Dementia/	148,649
2	Dement*.mp	114,488
3	Amentia*.mp	102
4	(major adj3 cognit* adj3 disorder*).mp	159
5	(alzheimer* or alzeimer* or (cortical adj4 sclerosis)).mp	140,775

6	((encephalopath* or cogniti* or neurocogniti*) adj4 (aids or acquired immunodeficiency syndrome or acquired immunodeficiency syndrome or hiv or human immunodeficiency virus or human immunodeficiency virus)).mp	3,302
7	"Pick Disease of the Brain"/	495
8	(Pick* disease).mp	3,308
9	(lobar adj3 atroph* adj3 brain).mp	10
10	Huntington Disease/	11,069
11	(Huntington* disease).mp	16,193
12	(Huntington* chorea).mp	1,349
13	Lewy Body Disease/	2,761
14	(Lewy bod* adj3 disease).mp	4,240
15	(cerebr* adj3 deteriorat*).mp	361
16	(cerebr* adj3 insufficien*).mp	2,079
17	((frontotemporal or fronto temporal or corticobasal or cortico basal or frontal lobe*) adj4 (degenerati* or dysfunction*)).mp	5,217
18	((cognit* or memory or cerebr*) adj3 (declin* or impair* or los* or deteriorat* or degenerat* or insufficien*)).mp	106,843
19	Cognitive Dysfunction/	8,749
20	(MCI or (mild adj2 cognit* impair*)).ti,ab.	20,332
21	Or/1-20	314,147
22	<i>(Intervention* or therap* or treatment* or program* or manage* or prevent* or diagnos* or polic*).mp</i>	12,485,776
23	exp Cognitive Therapy/	23,692
24	(cognit* adj3 therap*).mp	30,470
25	(cognit* psycho therap* or cognit* psychotherap*).mp.	119
26	(cognit* adj3 training).mp	3,571
27	(cognit* adj3 rehab*).mp	1,911
28	Or/23-27	36,923
29	exp Drug Therapy/	1,246,404
30	(Drug* or medicine* or pharmacotherap* or pharmaco* therap*).ti,ab.	1,838,638
31	exp Cholinesterase Inhibitors/	47,229
32	cholinesterase agent*.mp	30
33	cholinesterase inhibitor*.mp	21,340
34	exp Antipsychotic Agents/	115,322
35	(Tranquili* adj3 (agent* or drug*)).mp	12,096
36	Antipsychotic*.mp	63,916

37	(neuroleptic adj3 (agent* or drug*)).mp	3,296
38	exp Serotonin Uptake Inhibitors/	34,982
39	(serotonin uptake inhibitor* or serotonin reuptake inhibitor*).mp or ssri*.ti,ab	25,984
40	exp Benzodiazepines/	62,786
41	Benzodiazepine*.mp	42,836
42	exp "Hypnotics and Sedatives"/	115,358
43	(Sedative adj3 (effect* or agent*)).mp	5,467
44	(memantine or donepezil or rivastigmine or galantamine or souvenaid or risperidone or haloperidol or olanzapine or quetiapine or citalopram or dextromethorphan or carbamazepine or mirtazapine or sertraline or moclobemide or trazodone or melatonin or ramelteon or methylphenidate).mp	105,057
45	Or/29-44	3,080,487
46	exp Exercise Therapy/	42,856
47	Exercis*.mp	335,419
48	(Physical activit* or physical training).mp.	99,409
49	(Aerobic* or arobian*).mp	81,338
50	exp Exercise/	166,405
51	Or/46-50	497,630
52	(social adj3 activit*).mp	9,247
53	(social adj3 engag*).mp	2,774
54	(social adj3 stimul*).mp	2,178
55	Or/52-54	14,003
56	exp Psychotherapy/	180,508
57	(psycholog* therap* or psychotherap*).mp	85,389
58	((behavio?r* adj3 therap*) or (conditioning adj3 therap*)).mp	47,185
59	exp Counseling/	40,343
60	Counsel?ing.mp	89,908
61	psychosocial support systems/	145
62	((Psychosocial or psycho social) adj3 (support or interven* or care)).ti,ab	11,193
63	Or/56-62	315,606
64	exp Complementary Therapies/	208,840
65	((Alternative or compl?ment* or traditional) adj3 (medicine* or therap*)).mp	101,303
66	Acupunct*.mp	25,265
67	(herb* adj3 (tea or remedy or remedies or medicine*)).ti,ab.	16,075

68	Ginkgo.ti,ab	346
69	homeopath*.mp	6,178
70	((music or art or aroma or light or photo or pet or pets) adj3 therap*).ti,ab	16,656
71	Massage.ti,ab	9,025
72	(mind adj3 body).ti,ab	4,035
73	Phototherapy/	7,273
74	Or/64-73	302,897
75	exp Advance care planning/	8,277
76	(Advance? adj3 (care or medical or healthcare) adj3 plan*).mp	3,552
77	(decision* adj3 (aid* or support)).mp	41,646
78	Or/75-77	46,897
79	Case Management/	9,516
80	(communicati* adj3 skill* adj3 training).mp	1,283
81	(dementia care adj3 map*).mp	92
82	((person* or patient*) adj3 cent* adj3 care).mp	23,552
83	Or/79-82	34,244
84	("Resources for Enhancing Alzheimer's Caregiver Health" or "Strategies for Relatives").ti,ab.	88
85	Caregivers/ed [Education]	2,484
86	CAREGIVERS/px [Psychology]	18,509
87	Self-Help Groups/	8,626
88	exp Social support/	63,885
89	Or/84-88	87,559
90	Diagnosis, Computer-Assisted/	21,241
91	Telemedicine/	17,577
92	(Telemedicine or tele medicine).mp	21,573
93	exp Computers, Handheld/	5,107
94	((smart adj2 (phone* or device* or tablet*)) or smartphone*).mp	8,280
95	cognitive aid*.mp.	138
96	Reminder*.ti,ab	10,667
97	Robot*.mp	38,250
98	Or/90-97	102,392
99	22 or 28 or 45 or 51 or 55 or 63 or 74 or 78 or 83 or 89 or 98	13,800,589
100	21 and 99	208,431
101	randomized controlled trial.pt	462,693
102	controlled clinical trial.pt	92,457
103	(randomized or randomised).ab	495,756

104	Placebo.ab	189,758
105	drug therapy.fs	2,024,910
106	Randomly.ab	292,598
107	Trial.ab	431,012
108	Groups.ab	1,806,682
109	Or/101-108	4,294,404
110	randomized controlled trial.pt	462,693
111	(Cluster* adj2 randomi*).tw	9,224
112	((communit* adj2 intervention*) OR (communit* adj2 randomi*)).tw	6,858
113	Group* randomi*.tw	2,846
114	Or/111-113	18,443
115	intervention?.tw	782,326
116	cluster analysis/	56,328
117	health promotion/	66,499
118	program evaluation/	56,711
119	health education/	57,721
120	Or/115-119	965,052
121	114 OR 120	968,364
122	110 OR 121	1,366,397
123	risk.mp.	2,178,921
124	exp cohort studies/	1,751,258
125	between group.tw	21,162
126	Or/123-125	3,451,482
127	(non random* or nonrandom*).mp	33,945
128	Non-Randomized Controlled Trials as Topic/	359
129	quasi.mp	41,169
130	(natural adj3 experiment).mp	1,724
131	instrumental variable*.mp	1,969
132	Cohort.mp	516,750
133	before-after.mp	4,519
134	(before adj2 after adj study).mp.	1,810
135	Controlled Before-After Studies/	329
136	(difference-in-difference* or diff-in-diff).mp	1,782
137	regression discontinuity.mp	223
138	Historically Controlled Study/	139
139	historical* control.mp	3,400
140	Interrupted Time Series Analysis/	435

141	Interrupted Time Series.mp	2,280
142	Case-control.mp	287,943
143	Case-Control Studies/	249,334
144	Match*.mp	419,961
145	Propensity.mp	47,848
146	Propensity Score/	5,596
147	Or/127-146	1,205,777
148	126 or 147	4,094,244
149	Developing Countries.sh,kf.	81,106
150	(Africa or Asia or Caribbean or West Indies or South America or Latin America or Central America).hw,kf,ti,ab,cp.	242,209
151	(Afghan* or Albania* or Algeria* or Angola* or Anguilla* or Antigua* or Barbuda* or Argentina* or Armenia* or Azerbaijan* or Azeri or Bangladesh* or Barbados* or Benin* or Belarus* or Byelorussian or Belarus* or Belorussia* or Belize* or Bhutan* or Bolivia* or Bosnia* or Herzegovina* or Hercegovina* or Botswana or Botsuana or Motswana or Batswana or Brasil* or Brazil* or Burkina Faso or Burkina Fasso or Burkina* or Burundi* or Urundi* or Cambodia* or Cameroon* or Cameron* or Cape Verde* or Cabo Verde or Central African Republic or Chad* or Tchad* or Chile* or China or Chinese or Colombia* or Columbia* or Comoros or Comoro Islands or Comores or Comoran or Mayotte or Congo* or Costa Rica* or Cote d'Ivoire or Ivory Coast or Ivorian* or Cook Islands or Cuba* or Croat* or Djibouti* or Dominica* or East Timor or East Timur or Timor Leste or Timorese or Ecuador* or Equador* or Egypt* or El Salvador or Salvadoran or Eritrea* or Ethiopia* or Fiji* or Gabon* or Gambia* or Gaza or Georgia Republic or Georgian or Abkhazia* or Abchasia* or South Ossetia* or Ghana* or Grenada or Grenadian or Guatemala* or Guinea* or Guinea Bissau or Guian* or Guyana or Haiti* or Hondura* or India or Indian or Indonesia* or Iran* or Iraq* or Jamaica* or Jordan* or Kazakhstan* or Kazakh or Kenya* or Kiribati or Korea* or Kosovo or Kosova* or Kyrgyzstan or Kirghizia or Kyrgyz or Kirghiz or Kirgizstan or Lao PDR or Laos or Laotian or Lebanon or Lebanese or Lesotho or Mosotho or Basotho or Liberia* or Libya* or Macedonia* or FYROM or Madagasca* or Malagasy or Malaysia* or Malaya* or Malay or Sabah or Sarawak or Malawi* or Maldives or Maldivan or Mali or Malian or Marshall Islands or Marshallese or Mauritania* or Mauriti* or Agalega Islands or Mexico or Mexican or Micronesia* or Middle East* or Moldova* or Moldovia* or Transnistria* or Mongolia* or Montenegri* or	2,805,600

	Montserrat* or Morocc* or Mozambique or Mozambican or Myanmar* or Myanma or Burma or Burmese or Namibia* or Nauru* or Niue or Nepal* or Nicaragua* or Niger or Nigerien or Nigeria* or Oman* or Pakistan* or Palau* or Palestine or Palestinian or Panama or Panamanian or Paraguay* or Papua New Guinea* or Peru or Peruvian or Philippines or Philipines or Phillipines or Phillippines or Filipino or Philipino or Philippino or Phillipino or Phillippino or Rwanda* or Ruanda* or Saint Helen* or St Helen* or Saint Kitts or St Kitts or Kittian or Nevis* or Saint Lucia* or St Lucia* or Saint Vincent or St Vincent or Vicentian or Grenadines or Samoa* or Sao Tome* or Senegal* or Serbia* or Seychell* or Sierra Leone* or Sri Lanka* or Ceylon or Solomon Island* or Somali* or South Africa* or Sudan or Sudanese or Surinam* or Swaziland or Swazi or Eswatini or Syria or Syrian or Tajikistan or Tadzhikistan or Tadjikistan or Tajik or Tadzhi or Tanzania* or Thailand or Thai or Togo or Togolese or Tonga* or Tunisia* or Tokelau or Trinidad* or Tobago* or Turkey or Turkish or Turks or Turkmenistan or Turkmen or Tuvalu* or Uganda* or Ukraine or Ukrainian or Uruguay* or Uzbekistan* or Uzbek or Vanuatu or Venezuela* or Vietnam* or Viet Nam or Wallis Futuna or West Bank or Yemen* or Zambia* or Zimbabwe*).hw,kf,ti,ab,cp.	
152	((developing or less* developed or under developed or underdeveloped or middle income or low* income or underserved or under served or deprived or poor*) adj (countr* or nation? or population? or world)).ti,ab.	85,468
153	((developing or less* developed or under developed or underdeveloped or middle income or low* income) adj (economy or economies)).ti,ab.	440
154	(low* adj (gdp or gnp or gross domestic or gross national)).ti,ab.	217
155	(low adj3 middle adj3 countr*).ti,ab.	11,181
156	(lmic or lmics or third world or lami countr*).ti,ab.	5,792
157	transitional countr*.ti,ab.	146
158	Or/149-157	2,945,907
159	100 and (109 or 122 or 148) and 158	8,278
160	limit 159 to (comment or editorial or letter)	74
161	159 not 160	8,204
162	limit 161 to yr="2008 -Current"	6,322
163	exp animals/ not humans.sh.	4,496,553
164	162 not 163	5,786

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study selection

Search results from the database searches will be exported to a bibliographic reference manager and deduplicated. Two researchers will independently screen articles at the title and abstract level for eligibility. Full text for articles deemed eligible at this stage will be retrieved, including articles where no abstract was available at the first screening. Articles describing the same study will be linked together. Full-text articles will be independently assessed for inclusion eligibility by two researchers. Deviating decisions on inclusion will be resolved by discussion and consensus between the two researchers. If no consensus is reached by the two researchers, we will consult with a third researcher for a final decision on inclusion. We will record rates of agreement between researchers independently screening abstracts and full texts to measure the extent of disagreement using the kappa statistic. We will take a kappa of >0.8 as indication of ‘very good’ agreement.[36]

Inclusion and exclusion of studies at each stage will be illustrated with a PRISMA flow chart.[37] A list of included and excluded studies (with primary exclusion reason) will be made available.

Data extraction

Two researchers will independently extract the information listed in Box 3 from included studies. Selection of data to be extracted was informed by the review question and by practical insights regarding data extraction and synthesis from non-randomised studies.[38,39] We will contact authors of included abstracts to obtain full details of their studies if the information is not available from abstracts.

BOX 3: DATA TO BE EXTRACTED FROM INCLUDED STUDIES

- Publication details.
- Source of funding for the study.
- Geographical location.
- Care setting.
- Study design: description and coding of the study design and how causality of a treatment effect was established, including which covariates were used in the analysis to control for confounding and judgement about whether criteria for causality for the specific study design were met (in the case of non-randomised studies).
- Participant details, including type of dementia and representativeness of local/regional/national population with dementia.
- Intervention: brief description of the intervention in terms of its aims, implementation and intervention details, including e.g. duration and intensity of the intervention, dosage of drugs, existence of a protocol or manual for psychosocial, training or education interventions, and other details that allow an informed judgement about the comparability of interventions within the same type of treatment.
- Comparator: description of the comparison group and the intervention received by them (if any), including a note on statistically significant differences in baseline characteristics between experimental and control groups.
- Outcomes: primary and secondary outcomes of the study, including information on how they were measured (instruments used).
- Results: effect size and measure of its variance for the primary outcome and for any other outcomes mentioned in the abstract or executive summary of the study. Preference will be given to adjusted effect sizes (i.e. taking into account covariates that might not be balanced across experimental and control group), and in cases where several adjusted results are presented we will extract the one where selection bias is best controlled (either through design or analysis, e.g., inclusion of most relevant confounding variables).
- Risk of bias information.

Risk of bias

We will assess the internal validity of included studies using appropriate tools. For RCTs, we will use the Cochrane Collaboration's recently updated risk of bias tool (RoB 2.0).[40]

1
2
3 We will use the Cochrane Collaboration’s ROBINS-I tool to assess risk of bias in non-
4 randomised studies.[41]
5
6
7

8 **Data synthesis**
9

10 We will first describe the interventions that have been evaluated in rigorous study designs in
11 LMICs and summarise the features of the intervention, where they were studied,
12 characteristics of the studies, and their findings. We are planning to tabulate interventions
13 according to who they are targeted at (person living with dementia, their carers, care
14 professionals and care systems), aim of the intervention (secondary prevention, treatment,
15 disease management, coping with the disease and caring for people living with dementia,
16 managing the impact of dementia on the care system), intervention type (including, but not
17 limited to, pharmaceuticals, cognitive therapy, technological interventions, exercise, training,
18 diagnosis, organisation of care, financing of care, policy interventions), and outcomes studied.
19
20
21
22
23
24
25

26 Potentially relevant outcomes for this systematic review can be characterised by their type and
27 the stakeholder group they refer to. A draft list of potentially relevant outcomes and their
28 stakeholder groups according to which our analysis can be structured is provided in the online
29 supplementary table. The list is subject to change after reviewing the outcomes used in
30 included studies, which might use other outcomes that could necessitate a different
31 categorisation.
32
33
34
35
36

37
38 We will use the GRADE approach to rate the quality of evidence for each intervention.[42]
39
40
41

42 *Quantitative synthesis*
43

44 We will explore the feasibility of conducting quantitative synthesis of treatment effects
45 through traditional pair-wise and network meta-analysis. Feasibility of quantitative synthesis
46 will be assessed for each intervention studied in our sample of included studies. We will assess
47 the similarity of the specific intervention in each study with other candidate interventions for
48 a meta-analysis, the participants in the studies where this intervention was evaluated, and
49 whether the same outcome was used. Quantitative synthesis can only be conducted for studies
50 reporting the same outcome, although individual studies may use different instruments to
51 measure this (e.g. the MMSE and ADAS-cog for cognition, and the Texas Functional Living
52 Scale and Barthel scale for activities of daily living).
53
54
55
56
57
58
59
60

We will assess the feasibility to conduct both traditional pairwise and network meta-analysis. Pooled estimates are calculated as weighted averages of the treatment effects in included studies, where weights are assigned to each study based on its precision.[43] Network meta-analysis extends pairwise meta-analysis by incorporating both direct evidence about the relative effectiveness of interventions that have been compared to each other in a primary study and indirect evidence about the relative effectiveness of interventions that were never directly compared to each other, but are connected through a network of other interventions for which direct comparisons exist. In addition, network meta-analysis can be a valuable tool in delineating the effects of individual components of complex interventions, as recently shown in a network meta-analysis of multi-component interventions for dementia caregiver depression.[44] The validity of treatment effect estimates obtained through network meta-analysis depends on the similarity of the various direct comparisons in the network with respect to relevant treatment effect modifiers (e.g. severity of disease; age of participants; risk of bias due to study design and implementation) and consistency of treatment effects obtained from direct and indirect comparisons.[45]

It is anticipated that in our sample of included studies, there will be underlying differences between individual studies of the same intervention, in particular with respect to the details of the intervention and the setting. For example, a training intervention in one study is unlikely to be exactly the same intervention as in another study, even if a protocol is used to standardise the intervention, because, for example, the individual delivering the training changes. Such differences do not preclude pooling study results, but the heterogeneity in treatment effects resulting from underlying differences needs to be taken into account when assigning weights to studies for a pooled estimate. Our default will therefore be to use a random-effects model, which takes into account between-study variation and assumes that included studies come from different populations, with unique details of the intervention and conditions of the study. The true treatment effect can therefore vary from study to study.[46]

Subgroup analysis

While a random-effects model takes into account between-study variation, it does not explain heterogeneity. We will aim to use subgroup analysis and meta-regression to identify any study-level characteristics that might explain variation in treatment effects. Potential candidate covariates for subgroup analysis and meta-regression are study design and quality (within RCTs: risk of bias; within non-RCTs: analytical method employed, e.g. instrumental

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

variable, risk of bias), intervention details (e.g. drug dose; intensity of training; intensity of stimulation therapy), and setting (by country; by bracket of gross national income; by rural vs. urban setting). However, subgroup analysis will only produce meaningful insights when enough studies are included in each subgroup to detect any difference by the selected covariate (as opposed to a chance finding) and meta-regression should not be conducted for samples of less than 10 studies.[47] Given that we do not expect to identify a large number of robust dementia intervention studies in LMICs, it is unlikely that there will be sufficient studies of a given intervention with a specific outcome to allow meaningful subgroup analysis and meta-regression.

In cases where interventions were evaluated both by RCTs and non-randomised studies, we will obtain separate pooled effects for the two study types.[17] We will extract information on study design characteristics that will allow us to examine these as potential sources of heterogeneity.[38]

Exploring meta-bias

For each intervention-outcome pair, we will first assess in a funnel plot whether asymmetry exists with respect to expected random variation of treatment effects around the pooled effect estimate with decreasing study precision. Funnel plots are used to detect possibly ‘missing’ smaller studies with larger or smaller treatment effects than what would be expected by chance alone, for which publication bias is one possible explanation.[48] We will then use contour-enhanced funnel plots to assess whether any observed asymmetry is likely due to publication bias favouring the publication of statistically significant results.[49]

We anticipate identifying only a small number of studies eligible for inclusion in our quantitative review (meeting the criteria of being conducted in a LMIC and using a robust study design). In a scenario where not more than one LMIC study exists for any combination of intervention and outcome, pairwise meta-analysis will become impossible. For network meta-analysis, the existence of only a handful of LMIC studies, even if a common comparator (e.g., standard care) exists, makes it difficult to assess whether the assumptions of similarity (with respect to treatment effect modifiers) and consistency (agreement between direct and indirect estimates of treatment effect) hold. In case of a lack of eligible studies meeting our primary inclusion criteria, we will use our secondary set of inclusion criteria for studies using less robust research designs and will explore the feasibility of quantitative synthesis of these.

Should quantitative synthesis of LMIC studies not be feasible due to a lack of studies reporting the same outcome, we will pursue an alternative way of obtaining pooled estimates of the comparative effectiveness of dementia interventions relevant for LMICs, as outlined below. In a scenario where we are unable to identify enough primary studies of dementia interventions in LMICs, we will quantitatively synthesise available evidence from methodologically robust studies from high-income countries, as identified in the MODEM toolkit (www.modem-dementia.org.uk). We will discuss existing interventions with dementia experts from the STRiDE partner countries to identify those that have the highest relevance for LMICs. We will then extract relevant information from studies meeting our study design inclusion criteria in the MODEM data base and obtain pooled estimates for the effectiveness and comparative effectiveness of these interventions. We will develop a separate protocol for this approach should it become necessary (i.e. in the case of not identifying eligible studies in LMICs).

Patient and public involvement

No people living with dementia were involved in the development of this protocol.

ETHICS AND DISSEMINATION

No primary data collection will be conducted. We will include published reports of studies and will synthesise results of these at the aggregate level. We therefore did not seek ethics approval.

We plan to publish the findings of this systematic review both as a peer-reviewed article and in formats more accessible to people living with dementia, their carers, policy-makers, care professionals, and lay audiences, including on a website and DVD and in brief evidence summaries.

COMPETING INTERESTS

The authors declare no competing interests.

FUNDING

This work is conducted as part of the "Strengthening responses to dementia in developing countries" (STRiDE) project, supported by the UK Research and Innovation's Global Challenges Research Fund (ES/P010938/1). The funder was not involved in the development of this protocol at any stage.

AUTHORS' CONTRIBUTIONS

ACH, DMD, HN and MSK defined the scope of the review and review question. DMD, HN and MSK developed inclusion/exclusion criteria. AF consulted on the databases to be searched and search terms used. MSK drafted the protocol. All authors reviewed the draft protocol along with the search strategy and contributed to a revised version. MSK acts as the guarantor of the manuscript.

REFERENCES

1 Prince M, Wimo A, Guerchet M, *et al*. World Alzheimer Report 2015: The Global Impact of Dementia. London: 2015.
<https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf> (accessed 21 May 2018).

2 Alzheimer's Association. What Is Dementia? 2018.<https://www.alz.org/what-is-dementia.asp> (accessed 25 Jun 2018).

3 Patel V. Mental health in low- and middle-income countries. *Br Med Bull* 2007;**81-82**:81-96. doi:10.1093/bmb/ldm010

4 Livingston G, Sommerlad A, Orgeta V, *et al*. Dementia prevention, intervention, and care. *Lancet* 2017;**390**:2673-734. doi:10.1016/S0140-6736(17)31363-6

5 World Health Organization. Global action plan on the public health response to dementia 2017-2025. Geneva: 2017.
<http://apps.who.int/iris/bitstream/handle/10665/259615/9789241513487-eng.pdf;jsessionid=991FCCD18EF2BA8839F7B6048A28757B?sequence=1> (accessed 29 May 2018).

6 Comas-Herrera A, Knapp M, Wittenberg R, *et al*. MODEM: A comprehensive approach to modelling outcome and costs impacts of interventions for dementia. Protocol paper. *BMC Health Serv Res* 2017;**17**:25. doi:10.1186/s12913-016-1945-x

7 Prince M, Comas-Herrera A, Knapp M, *et al*. World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future. London: : Alzheimer's Disease International (ADI) 2016.
<http://eprints.lse.ac.uk/67858/> (accessed 21 May 2018).

8 Rubin DB. For objective causal inference, design trumps analysis. *Ann Appl Stat* 2008;**2**:808-40. doi:10.1214/08-AOAS187

9 Holland PW. Statistics and Causal Inference. *J Am Stat Assoc* 1986;**81**:945-60.

- doi:10.2307/2289064
- 10 Spector A, Thorgrimsen L, Woods B, *et al.* Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia. *Br J Psychiatry* 2003;**183**:248–54. doi:10.1192/bjp.183.3.248
 - 11 Aguirre E, Hoare Z, Streeter A, *et al.* Cognitive stimulation therapy (CST) for people with dementia—who benefits most? *Int J Geriatr Psychiatry* 2013;**28**:284–90. doi:10.1002/gps.3823
 - 12 Molloy DW, Guyatt GH, Russo R, *et al.* Systematic Implementation of an Advance Directive Program in Nursing Homes. *JAMA* 2000;**283**:1437. doi:10.1001/jama.283.11.1437
 - 13 Teri L, Huda P, Gibbons L, *et al.* STAR: A Dementia-Specific Training Program for Staff in Assisted Living Residences. *Gerontologist* 2005;**45**:686–93. doi:10.1093/geront/45.5.686
 - 14 Livingston G, Barber J, Rapaport P, *et al.* Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial. *BMJ* 2013;**347**:f6276. doi:10.1136/BMJ.F6276
 - 15 Shamseer L, Moher D, Clarke M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;**350**:g7647. doi:10.1136/BMJ.G7647
 - 16 Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. *Acta Psychiatr Scand* 2009;**119**:252–65. doi:10.1111/j.1600-0447.2008.01326.x
 - 17 Reeves BC, Deeks JJ, Higgins JPT, *et al.* Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.* The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
 - 18 World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. Geneva: 2012. http://apps.who.int/iris/bitstream/handle/10665/75263/9789241564458_eng.pdf?sequence=1 (accessed 29 May 2018).
 - 19 O'Connor D, Green S, Higgins JPT. Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0.* The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
 - 20 Prince MJ, Acosta D, Castro-Costa E, *et al.* Packages of care for dementia in low- and middle-income countries. *PLoS Med* 2009;**6**:e1000176. doi:10.1371/journal.pmed.1000176
 - 21 Cochrane Effective Practice and Organisation of Care (EPOC). What study designs can be considered for inclusion in an EPOC review and what should they be called? EPOC Resources for review authors. 2017.
 - 22 Reeves BC, Wells GA, Waddington H. Quasi-experimental study designs series—paper 5: a checklist for classifying studies evaluating the effects on health interventions—a taxonomy without labels. *J Clin Epidemiol* 2017;**89**:30–42. doi:10.1016/J.JCLINEPI.2017.02.016

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
- 23 Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S., eds. *Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.* The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
- 24 Taljaard M, McGowan J, Grimshaw JM, *et al.* Electronic search strategies to identify reports of cluster randomized trials in MEDLINE: low precision will improve with adherence to reporting standards. *BMC Med Res Methodol* 2010;**10**:15. doi:10.1186/1471-2288-10-15
- 25 Wilczynski NL, McKibbin KA, Walter SD, *et al.* MEDLINE clinical queries are robust when searching in recent publishing years. *J Am Med Informatics Assoc* 2013;**20**:363–8. doi:10.1136/amiajnl-2012-001075
- 26 Dias A, Dewey ME, D’Souza J, *et al.* The effectiveness of a home care program for supporting caregivers of persons with dementia in developing countries: a randomised controlled trial from Goa, India. *PLoS One* 2008;**3**:e2333. doi:10.1371/journal.pone.0002333
- 27 Menezes AV, Aguiar A da S de, Alves EF, *et al.* [Effectiveness of a cognitive-motor/physiotherapeutical therapy intervention in institutionalized older adults with mild cognitive impairment and mild dementia]. *Cien Saude Colet* 2016;**21**:3459–67. doi:10.1590/1413-812320152111.17892015
- 28 Caramelli P, Laks J, Palmini ALF, *et al.* Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). *Arq Neuropsiquiatr* 2014;**72**:411–7. <http://www.ncbi.nlm.nih.gov/pubmed/24964105> (accessed 15 Aug 2018).
- 29 Guerra M, Ferri CP, Fonseca M, *et al.* Helping carers to care: the 10/66 dementia research group’s randomized control trial of a caregiver intervention in Peru. *Rev Bras Psiquiatr* 2011;**33**:47–54. <http://www.ncbi.nlm.nih.gov/pubmed/20602013> (accessed 15 Aug 2018).
- 30 Lam LC-W, Chan WC, Leung T, *et al.* Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial. *PLoS One* 2015;**10**:e0118173. doi:10.1371/journal.pone.0118173
- 31 Liu P, Kong M, Liu S, *et al.* Effect of reinforcing kidney-essence, removing phlegm, and promoting mental therapy on treating Alzheimer’s disease. *J Tradit Chinese Med = Chung i tsa chih ying wen pan* 2013;**33**:449–54. <http://www.ncbi.nlm.nih.gov/pubmed/24187864> (accessed 15 Aug 2018).
- 32 Chang F-Y, Huang H-C, Lin K-C, *et al.* The effect of a music programme during lunchtime on the problem behaviour of the older residents with dementia at an institution in Taiwan. *J Clin Nurs* 2010;**19**:939–48. doi:10.1111/j.1365-2702.2009.02801.x
- 33 Tate JA, Snitz BE, Alvarez KA, *et al.* Infection hospitalization increases risk of dementia in the elderly. *Crit Care Med* 2014;**42**:1037–46. doi:10.1097/CCM.0000000000000123
- 34 Franco C, Sola M del M, Justo E. [Reducing psychological discomfort and overload in Alzheimer’s family caregivers through a mindfulness meditation program]. *Rev Esp Geriatr Gerontol* 2010;**45**:252–8. doi:10.1016/j.regg.2010.03.006
- 35 Buettner LL, Fitzsimmons S. Promoting health in early-stage dementia: evaluation of a

- 12-week course. *J Gerontol Nurs* 2009;**35**:39–49. <http://www.ncbi.nlm.nih.gov/pubmed/19326828> (accessed 15 Aug 2018).
- 36 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;**33**:159–74. <http://www.ncbi.nlm.nih.gov/pubmed/843571> (accessed 25 Jun 2018).
- 37 Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;**6**:e1000097. doi:10.1371/journal.pmed.1000097
- 38 Becker BJ, Aloe AM, Duvendack M, *et al.* Quasi-experimental study designs series—paper 10: synthesizing evidence for effects collected from quasi-experimental studies presents surmountable challenges. *J Clin Epidemiol* 2017;**89**:84–91. doi:10.1016/J.JCLINEPI.2017.02.014
- 39 Aloe AM, Becker BJ, Duvendack M, *et al.* Quasi-experimental study designs series—paper 9: collecting data from quasi-experimental studies. *J Clin Epidemiol* 2017;**89**:77–83. doi:10.1016/J.JCLINEPI.2017.02.013
- 40 Higgins JP, Sterne JA, Savovic J, *et al.* A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (editors). *Cochrane Methods. Cochrane Database Syst Rev* 2016;**10** (suppl). doi:dx.doi.org/10.1002/14651858.CD201601
- 41 Sterne JA, Hernán MA, Reeves BC, *et al.* ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016;**355**:i4919. doi:10.1136/bmj.i4919
- 42 Schuenemann H, Brozek J, Guyatt G, *et al.* *Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach.* 2013. <https://gdt.gradeapro.org/app/handbook/handbook.html> (accessed 7 Nov 2018).
- 43 Lau J, Ioannidis JPPA, Schmid CH, *et al.* Quantitative Synthesis in Systematic Reviews. *Ann Intern Med* 2015;**820**–6. <http://annals.org/article.aspx?articleid=710939>
- 44 Liew TM, Lee CS. Reappraising the Efficacy and Acceptability of Multicomponent Interventions for Caregiver Depression in Dementia: The Utility of Network Meta-Analysis. *Gerontologist* Published Online First: 31 May 2018. doi:10.1093/geront/gny061
- 45 Cipriani A, Higgins JPT, Geddes JR, *et al.* Conceptual and Technical Challenges in Network Meta-analysis. *Ann Intern Med* 2013;**159**:130. doi:10.7326/0003-4819-159-2-201307160-00008
- 46 Borenstein M, Hedges L V., Higgins JPT, *et al.* A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods* 2010;**1**:97–111. doi:10.1002/jrsm.12
- 47 Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.* The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
- 48 Sterne JAC, Sutton AJ, Ioannidis JPA, *et al.* Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;**343**:d4002. doi:10.1136/BMJ.D4002
- 49 Peters JL, Sutton AJ, Jones DR, *et al.* Contour-enhanced meta-analysis funnel plots help

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

distinguish publication bias from other causes of asymmetry. *J Clin Epidemiol* 2008;**61**:991–6. doi:10.1016/j.jclinepi.2007.11.010

For peer review only

Online supplementary material

Effectiveness of interventions for dementia in low- and middle-income countries: Protocol for a systematic review, pairwise and network meta-analysis

Maximilian Salcher-Konrad, Huseyin Naci, David McDaid, Suvarna Alladi, Déborah Oliveira, Andra Fry, Shereen Hussein, Martin Knapp, Christine Musyim, David M. Ndeti, Mariana Lopez Ortega, Adelina Comas-Herrera

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary table: Draft outcome categories

Types of outcomes	Outcomes relevant for:		
	Person living with dementia	Carer	Care system/society
Diagnosis	X		X
Clinical outcomes			
- Cognition	X		
- Depression and anxiety	X		
- Behaviour	X		
- Physical health	X		
Quality of life and functioning			
- Quality of life of person with dementia	X		
- Activities of daily living/IADL	X		
- Social and role functioning	X		
Carer outcomes			
- Quality of life of carer		X	
- Carer burden		X	
- Mental health of carer		X	
- Carer economic outcomes		X	
- Carer professional development		X	
- Carer retention		X	
Care provided			
- Satisfaction with care	X	X	X
- Care setting (institutionalisation)	X		
- Appropriateness and quality of care (e.g. use of feeding tubes)	X		X
Economic outcomes			
- Service use and cost reductions			X
- Out-of-pocket payments	X	X	
- Opportunity costs	X	X	X
End-of-life			
- Place of death	X		
- Decision-making	X		

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on page #
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2, 5
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	27
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	26
Sponsor	5b	Provide name for the review funder and/or sponsor	26
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	26
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6-11
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	11-13
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits such that it could be	14-20

		repeated	
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	21
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	21
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, duplicate), any processes for obtaining and confirming data from investigators	21
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	22
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7-8, Online Supplement
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	22-23
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	23
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ)	23-25
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	24-25
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	23
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	25
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	23

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Effectiveness of interventions for dementia in low- and middle-income countries: Protocol for a systematic review, pairwise and network meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027851.R1
Article Type:	Protocol
Date Submitted by the Author:	10-Apr-2019
Complete List of Authors:	Salcher-Konrad, Maximilian; London School of Economics and Political Science, Personal Social Services Research Unit (PSSRU) Naci, Huseyin; London School of Economics and Political Science, Health Policy McDaid, David ; London School of Economics and Political Science, Personal Social Services Research Unit (PSSRU) Alladi, Suvarna; NIMHANS, Bangalore, India Oliveira, Deborah; Federal University of Sao Paulo (UNIFESP); University of Nottingham Institute of Mental Health Fry, Andra; London School of Economics and Political Science, Library Hussein, Shereen; University of Kent, Personal Social Services Research Unit (PSSRU) Knapp, Martin; London School of Economics and Political Science, Personal Social Services Research Unit (PSSRU) MUSYIMI, CHRISTINE; AFRICA MENTAL HEALTH FOUNDATION, RESEARCH Ndeti, David; Africa Mental Health Foundation; University of Nairobi Lopez-Ortega, Mariana; National Institute of Geriatrics, National Institutes of Health Comas-Herrera, Adelina; London School of Economics and Political Science, Personal Social Services Research Unit (PSSRU)
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Global health, Health services research, Public health
Keywords:	Dementia < NEUROLOGY, low and middle income countries, developing countries, alzheimer disease, lamics, systematic review

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Effectiveness of interventions for dementia in low- and middle-income countries: Protocol for a systematic review, pairwise and network meta-analysis

Maximilian Salcher-Konrad ^{*,1}, Huseyin Naci ², David McDaid ¹, Suvarna Alladi ³, Déborah Oliveira ^{4,5}, Andra Fry ⁶, Shereen Hussein ⁷, Martin Knapp ¹, Christine Musyimi ⁸, David M. Ndeti ^{8,9}, Mariana Lopez-Ortega ¹⁰, Adelina Comas-Herrera ¹

* Corresponding author.
Address: PSSRU, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, United Kingdom.
Email: m.salcher@lse.ac.uk
Telephone: +44 (0) 20 7955 6959
¹ Personal Social Services Research Unit (PSSRU), London School of Economics and Political Science, London, United Kingdom.
² Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.
³ National Institute of Mental Health and Neuro Sciences, Bangalore, India.
⁴ Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil.
⁵ Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom.
⁶ Library, London School of Economics and Political Science, London, United Kingdom.
⁷ Personal Social Services Research Unit (PSSRU), University of Kent, Canterbury, United Kingdom.
⁸ Africa Mental Health Foundation, Nairobi, Kenya.
⁹ University of Nairobi, Nairobi, Kenya.
¹⁰ National Institute of Geriatrics, National Institutes of Health, Mexico City, Mexico.

Word count, excluding title page, abstract, references, figures and tables: 4,384

ABSTRACT

Introduction: There are more people living with dementia in low- and middle-income countries (LMICs) than in high-income countries. Evidence-based interventions to improve the lives of people living with dementia and their carers are needed, but a systematic mapping of methodologically robust studies in LMICs and synthesis of the effectiveness of dementia interventions in these settings is missing.

Methods and analysis: A systematic review and meta-analysis will be conducted to answer the question: Which dementia interventions were shown to be effective in LMICs and how do they compare to each other? Electronic database searches (MEDLINE, EMBASE, PsycINFO, CINAHL plus, Global Health, WHO Global Index Medicus, Virtual Health Library, Cochrane CENTRAL, Social Care Online, BASE, MODEM toolkit, Cochrane Database of Systematic Reviews) will be complemented by hand searching of reference lists and local knowledge of existing studies from an international network of researchers in dementia from LMICs. Studies will be eligible for inclusion if they were published between 2008 and 2018, conducted in LMICs and evaluated the effectiveness of a dementia intervention using a study design that supports causal inference of the treatment effect. We will include both randomised and non-randomised studies due to an anticipated low number of well-conducted randomised trials in LMICs and potentially greater external validity of non-randomised studies conducted in routine care settings. In addition to narrative synthesis of the interventions, feasibility of pairwise and network meta-analyses will be explored to obtain pooled effects of relative treatment effects.

Ethics and dissemination: Secondary analysis of published studies, therefore no ethics approval required. Planned dissemination channels include a peer-reviewed publication as well as a website, DVD and evidence summaries.

Registration details: PROSPERO CRD42018106206 (www.crd.york.ac.uk/prosperto)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STRENGTHS AND LIMITATIONS OF THE STUDY

- This protocol defines the scope, inclusion/exclusion criteria, and analytical approach for the first comprehensive assessment of methodologically robust dementia intervention studies in low- and middle-income countries (LMICs), the setting where most people with dementia currently live.
- Eligible study designs include both randomised trials and non-randomised studies supporting causal inference of treatment effects, with stringent eligibility criteria applied for the latter.
- Planned analyses include a narrative synthesis mapping out the interventions studied in LMICs as well as traditional pairwise and network meta-analysis, capable of yielding relative treatment effect estimates for interventions that have been compared either directly or indirectly (through a common comparator) to each other.
- A low number of studies may be eligible for inclusion, potentially limiting the scope for quantitative meta-analysis.

INTRODUCTION

More people with dementia are now living in low- and middle income countries (LMICs) compared to high-income countries.[1] Dementia is described by the Alzheimer's Association as "an overall term that describes a group of symptoms associated with a decline in memory or other thinking skills severe enough to reduce a person's ability to perform everyday activities." [2]. Like other mental disorders, it places a significant burden on societies in LMICs, where care is often provided by family members and/or financed out-of-pocket, magnifying its impact beyond the individual living with the condition.[3] While no curative treatment for dementia exists, a range of interventions aimed at improving the lives of people living with dementia and their carers have been developed and progress made in evaluating and understanding which of these are effective.[4] Despite the large and increasing burden of dementia in LMICs, these interventions have been primarily evaluated in high-income settings. Better understanding of the impact of dementia in LMICs and how people living with the disease can be better supported are therefore considered to be a priority.[5] Building capacity for research and policy-making is at the heart of the recently launched STRiDE project (www.stride-dementia.org), as part of which a systematic review of the effectiveness of dementia interventions in LMICs will be conducted.

Research on dementia and dementia-related interventions, many aiming to improve the quality of life of those who are affected by the condition and their carers, has increased considerably since it was recognised as a key challenge for care systems: in mid-2018, the Cochrane Database of Systematic Review (www.cochranelibrary.com) listed over 120 systematic reviews of dementia-related interventions carried out since 2000 by their Dementia and Cognitive Improvement Group. Evidence on effectiveness and cost-effectiveness of a variety of dementia interventions has been recently summarised by other groups, prime among them the MODEM project.[6] A comprehensive database of over 1,400 dementia intervention studies, along with a toolkit containing evidence summaries for decision-makers, people living with dementia and their carers was created (<http://toolkit.modem-dementia.org.uk/>).

The increase in knowledge about disease aetiology, prevention and management is expected to contribute to better quality of life for people living with dementia and their carers through the implementation of evidence-based approaches to diagnosing, managing and enhancing quality of life while living with the disease. The World Health Organization,[5] organisations

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

representing people living with dementia and their families,[7] and researchers [4] are all calling for decision-makers to focus on such approaches when developing policies and programmes. Evidence-based practices are informed by studies with strong research designs supporting a causal link between an intervention (be it a drug, non-pharmacological therapy, organisational change, or another form of intervention) and improved outcomes in people living with dementia and their carers. While randomised controlled trials (RCTs) are considered the ‘gold standard’ of intervention studies, other study designs exist that allow researchers to draw causal conclusions about the effect of an intervention in the absence of RCTs and can provide essential evidence on ‘what works’.[8,9]

Interventions with proven positive impacts in high-income countries have previously been summarised in the MODEM dementia evidence toolkit. However, it is unclear whether interventions that showed beneficial effects in high-income settings, such as cognitive stimulation therapy for cognition and quality of life,[10,11] advance care planning,[12] training for formal carers (such as STAR)[13] and support for family carers (START),[14] are also effective in less-resourced settings, where awareness about dementia is lacking and dementia care may not be a policy priority. In this context, dementia is reported to be under-diagnosed and specialised care is often not available,[7] raising the question of which dementia interventions are effective in LMICs. Indeed, previously developed recommendations for packages of dementia care in LMICs were largely based on evidence from high-income countries,[7,15] indicating a need to better understand what works in LMICs. The aim of this systematic review is to help fill this research gap by identifying dementia interventions for which robust evidence on effectiveness in LMICs exists and to synthesise available evidence to determine which interventions have the most potential of achieving desired outcomes in these settings.

METHODS AND ANALYSIS

This systematic review and meta-analysis protocol adheres to the PRISMA-P checklist [16] and was registered on the PROSPERO platform (www.crd.york.ac.uk/prospero): CRD42018106206.

Review question

Which dementia interventions have been shown to be effective in low- and middle-income countries and how do they compare to each other?

Inclusion criteria

Population

We will include studies that have evaluated the effectiveness of an intervention in adults (18 years and over) living with dementia or their carers.

We will include studies in all stages (including early- to late-stage dementia) and different forms of dementia (e.g., Alzheimer's disease, vascular dementia, Lewy bodies dementia, and mixed dementias, as well as less common forms such as fronto-temporal dementia). We will also take into consideration risks of dementia associated with conditions such as HIV/AIDS that may be more prevalent in LMICs to ensure these are captured in our search strategy. Due to the particularly high risk of people with mild cognitive impairment (MCI) developing dementia (approximately one third will develop dementia over a period of three to ten years),^[17] we will also include studies focusing on this group.

Carers of people living with dementia include family members, other unpaid carers, as well as professional carers, irrespective of whether or not they are paid, and whether or not they are living with the person they care for.

Studies will be included if they were conducted in a country considered a LMIC according to the OECD categorisation at any time during the study period. The lists of aid recipient countries for the years 2008-2018 were used to identify LMICs (<http://www.oecd.org/development/financing-sustainable-development/development-finance-standards/historyofdaclistsofaidrecipientcountries.htm>).

We will include studies that were conducted entirely in LMICs, or (in the case of multi-country studies) where 50% or more of study participants received the intervention of interest in LMICs or where results were presented separately for participants in LMICs.

Intervention

One of the aims of this systematic review is to identify which interventions have been rigorously evaluated in LMICs. The eligibility criteria for types of interventions are therefore deliberately kept open: we will include all interventions that aim to improve the lives of people living with dementia and their carers contingent on the intervention having been subjected to a rigorous evaluation (see eligible study designs below). We will apply an 'effectiveness'

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

perspective with respect to interventions, i.e. interventions are eligible when defined as such in a study and improved outcomes are expected through the intervention.[18] We will focus on people already living with dementia or MCI and their carers and will therefore exclude primary prevention studies (i.e. prevention of dementia in people without cognitive impairment).

Dementia interventions can vary in terms of who they are targeting (person living with dementia; unpaid carers; care professionals and care systems); what the aim of the intervention is (secondary prevention; treatment; disease management; coping with caring for people living with dementia; managing the impact of dementia on the care system); and their mechanism (including diagnosis; pharmacological treatment; cognitive therapy; technological interventions; training; exercise; sleep therapy; music therapy; organisation of care, including advance care directives and case management; support for carers; financing of care; policy interventions; and others).[4]

Comparison

All comparisons will be eligible, including active comparators, usual practice/standard care/placebo and no action.

Outcomes

Outcomes of dementia intervention studies are highly heterogeneous and may vary by who is affected (person living with dementia; their carer(s); wider society and care system) and type of outcome (clinical outcomes, such as cognitive, neurological, psychological, psycho-social; quality of life and functioning outcomes; care and delivery of care, such as the use of feeding tubes, hospitalisations, institutionalisations; economic outcomes; diagnosis rates; knowledge of the disease and ability to cope with caring for people with dementia). For example, recommendations on dementia interventions were recently made based on a review of the evidence on outcomes in domains ranging from, among others, cognition and neuropsychiatric outcomes to end-of-life care and care delivery.[4]

Given the broad range of potentially relevant outcomes, a search strategy that captures all of these is not feasible. Restricting inclusion criteria to certain types of outcomes would risk excluding potentially important parts of the evidence base for dementia interventions in LMICs. The impact of dementia is recognised to be experienced by different people and at

different levels, including by people living with dementia, their carers, communities and the care system and wider society,[19] and interventions therefore need to take all of these perspectives into account.[5]

Study design

The research question we aim to answer is what works in dementia in LMICs. We are therefore interested in the effect that an intervention had on outcomes in people receiving the intervention, their carers and the wider care system.[20] Accordingly, we will apply a causal inference framework in this review: study designs eligible for inclusion are those that support a causal link between the intervention and observed outcomes. This includes experimental designs (RCTs and cluster-RCTs) as well as non-randomised designs suitable for causal inference, defined as “comparisons of ‘potential outcomes’ [...] under different treatment conditions on a common set of units.”[8] We will include both randomised and non-randomised studies due to an anticipated low number of well-conducted randomised trials in LMICs, based on previous work (searches conducted for the MODEM evidence toolkit, and a previous review on packages of care for people living with dementia in LMICs [21]). Also, non-randomised studies may have greater generalisability beyond the studied environment when conducted in settings and populations closer resembling routine practice.

In order to maximise the number of eligible studies and synthesise as much robust evidence about dementia interventions in LMICs as possible, we will extend the eligibility criteria used by the Cochrane Effective Practice and Organisation of Care (EPOC) Group [22] to also include other quasi-experimental study designs in addition to those typically seen in methodologically robust evaluation studies (non-randomised controlled trials, controlled before-after studies, and interrupted time series studies). The label ‘quasi-experimental’ is discipline-specific and members of the Cochrane Non-Randomized Studies for Interventions Methods Group therefore developed a ‘label-free’ taxonomy of quasi-experimental studies that aims to define such studies through a series of questions in six domains.[23] We will use their checklist to guide the selection of studies by study design (see Table 1). Since we anticipate a shortage of methodologically robust studies of dementia interventions in LMICs, but still aim to synthesise the best available evidence that supports causal inference of treatment effects, we adapted the original checklist by removing restrictions to answer ‘yes’ to only one question in domains 2, 3, and 4. This will enable us to include several strong experimental and quasi-experimental study designs, including RCTs (including cluster-RCTs); non-randomised

controlled trials; controlled before-after studies; interrupted time series studies; difference-in-differences studies; instrumental variables studies; regression discontinuity design studies; and other study designs that employ methods such as propensity score matching that attempt to control for observed and unobserved confounders.

As a contingency plan in case no such studies can be identified in LMICs, we define a secondary set of inclusion criteria to still capture intervention studies in LMICs with less robust designs but that could still inform our understanding of what works in dementia in LMICs in the absence of better study designs. The secondary set of inclusion criteria will mirror the primary inclusion criteria, with the exception of study design. In the secondary set of inclusion criteria, studies will also be eligible for inclusion if they control only for observed confounders (criterion 4 in Table 1).

TABLE 1: CHECKLIST FOR ELIGIBLE STUDY DESIGNS (BASED ON REEVES ET AL.[23])

Feature	Eligible for inclusion if...
1. Was the intervention/comparator:	
Allocated to (provided for/administered to/chosen by) individuals?	Yes
Allocated to (provided for/administered to/chosen by) clusters of individuals?	Yes
Clustered in the way it was provided (by practitioner or organizational unit)?	Yes
2. Were outcome data available:	
After intervention/comparator only (same individuals)?	No
After intervention/comparator only (not all same individuals)?	No
Before (once) AND after intervention/comparator (same individuals)?	Yes
Before (once) AND after intervention/comparator (not all same individuals)?	Yes
Multiple times before AND multiple times after intervention/comparator (same individuals)?	Yes
Multiple times before AND multiple times after intervention/comparator (not all same individuals)?	Yes
3. Was the intervention effect estimated by:	
Change over time (same individuals at different time points)?	Yes

Change over time (not all same individuals at different time points)?	Yes
Difference between groups (of individuals or clusters receiving either intervention or comparator)?	Yes
4. Did the researchers aim to control for confounding (design or analysis)	
Using methods that control in principle for any confounding?	Yes
Using methods that control in principle for time-invariant unobserved confounding?	Yes
Using methods that control only for confounding by observed covariates?	No
5. Were groups of individuals or clusters formed by	
Randomisation?	Yes
Quasi-randomisation?	Yes
Explicit rule for allocation based on a threshold for a variable measured on a continuous or ordinal scale or boundary (in conjunction with identifying the variable dimension, below)?	Yes
Some other action of researchers?	Yes
Time differences?	Yes
Location differences?	Yes
Health care decision makers/practitioners?	Yes
Participants' preferences?	Yes
Policy maker?	Yes
On the basis of outcome?	No
Some other process? (specify)	-
6. Were the following features of the study carried out after the study was designed	
Characterisation of individuals/clusters before intervention?	Yes
Actions/choices leading to an individual/cluster becoming a member of a group?	Yes
Assessment of outcomes?	Yes
7. Were the following variables measured before intervention:	
Potential confounders?	Yes
Outcome variable(s)?	Yes

Publication type

We will include peer-reviewed journal articles, including primary publications of intervention studies and systematic reviews of these, and grey literature describing evaluations of dementia

interventions in LMICs (e.g., PhD theses and reports published by care system administrative bodies and non-governmental organisations). Systematic reviews are only eligible for inclusion if their focus is on LMICs (i.e., if LMICs were specified as geographical setting in their inclusion criteria) and we will use these to identify primary studies eligible for inclusion (eligible if 50% or more participants were in LMICs or results were reported separately for LMIC settings). We will also include conference abstracts, provided they contain information to assess eligibility for inclusion.

Exclusion criteria

Exclusion criteria are listed in Box 1.

BOX 1: EXCLUSION CRITERIA

We will exclude studies meeting any of the following conditions:

- Studies where less than 50% of participants received the intervention of interest in LMICs or where no results are available for a LMIC sub group
- Studies where no clear intervention was described
- Studies of associations between exposure and outcome (as opposed to causal links between intervention and outcome)
- Studies of primary prevention of dementia
- Studies where reports are not available in a language spoken by the international project team members (languages spoken include Arabic, Chinese, English, French, German, Bahasa Indonesia, Portuguese, Romanian, Spanish, Turkish, and others)
- Studies that do not attempt to control for unobserved confounding, including cohort studies, case-control studies, cross-sectional studies, and case series (unless these have applied methods to control for unobserved confounders)
- Narrative reviews; overview articles; editorials; commentaries; letters to the editor
- Studies where animals (as opposed to humans) received the intervention

In case no studies meeting our primary inclusion criteria for study design can be identified, we will apply secondary inclusion criteria as specified under “Study design” and will amend the exclusion criteria for study design accordingly.

Search strategy

We will conduct searches in bibliographic databases (Box 2), using text words, subject headings and other search functions that each database offers. We will limit the searches to studies published from 2008 to 2018 and, where possible, will use filters to exclude editorials, commentaries, and letters to the editor, as well as running a search filter for animal studies.

BOX 2: ONLINE DATABASES TO BE SEARCHED

- MEDLINE (via OVID)
- EMBASE (via OVID)
- PsycINFO (via OVID)
- CINAHL plus (via EBSCO)
- Global Health (via CABI)
- WHO Global Index Medicus (GIM, includes databases from the six WHO regions: AIM (AFRO), LILACS (AMRO/PAHO), IMEMR (EMRO), IMSEAR (SEARO), WPRIM (WPRO))
- Cochrane CENTRAL and Cochrane Database of Systematic Reviews
- Social Care Online
- BASE
- Virtual Health Library

In addition to the international databases listed above, we will consider additional national or regional databases through consultation with STRiDE partners in seven LMICs (Brazil, India, Indonesia, Jamaica, Kenya, Mexico, South Africa). These databases might not be available in English and we will capitalise on the variety of languages spoken in the STRiDE consortium to include these in our search strategy, if deemed of sufficient added value for the identification of studies meeting our inclusion criteria.

We will also make use of previous efforts to systematically capture studies evaluating the effectiveness of dementia interventions and will review studies identified by other authors for inclusion. First, we will review studies included in the MODEM Dementia Evidence Toolkit (<http://toolkit.modem-dementia.org.uk>). The MODEM toolkit contains over 1,400 primary studies of dementia interventions. While the primary focus of the toolkit was on high-income settings, studies from LMICs may be included in the database. Secondly, we will screen existing Cochrane systematic reviews of dementia interventions for primary studies conducted

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

in LMICs. We will review all Cochrane systematic reviews indexed in the Cochrane Library’s dementia and cognition topic.

In addition to database searches, we will scan the reference lists of included studies to capture potentially missed ones. We will use Google Scholar, Scopus and Web of Science to carry out citation searches for the included papers.

We will also capitalise on the expertise of STRiDE consortium partners (researchers and dementia advocacy groups) in seven LMICs (Brazil, India, Indonesia, Jamaica, Kenya, Mexico, South Africa), and an expanded network of STRiDE collaborators in other countries, to include published and unpublished studies from these and other countries meeting our eligibility criteria if they were not captured by database searches.

We will further search trials registers (clinicaltrials.gov and the International Clinical Trials Registry Platform) to identify ongoing or planned clinical trials of dementia interventions in LMICs.

We will capitalise on the expertise of LSE’s information specialist support team to finalise the search strategy.

Search terms

Search terms were selected to reflect the key concepts making up the review question: dementia interventions that have been studied using robust research designs in LMICs. Exemplary search terms for MEDLINE via OVID for the concepts of population and intervention, study design, and LMICs are provided in Table 2, including the number of hits for each search as per 10th October 2018. The search for MEDLINE will be translated for the other databases.

The ‘intervention’ concept provided in Table 2 (lines 22-98) includes both generic terms as well as a range of specific interventions that have been studied for dementia before, although usually in high-income countries. We based the list of specific interventions on a thorough review of the evidence, conducted as part of the Lancet commission,[4] and through revision by the international STRiDE consortium. While this might not be a comprehensive list of all interventions that have ever been studied for dementia, we aimed to increase the likelihood of

identifying relevant studies by combining generic search terms pertaining to interventions, therapies, etc. with specific intervention types and names of interventions, such as drug names.

We will use established study design and geographical location search filters to narrow down the number of results and will make adaptations as necessary to reflect our inclusion criteria. If such filters are not available for some databases, we will consider adapting the search filters used for MEDLINE.

The search filters for eligible study designs are provided in Table 2, rows 101-108 (for RCTs), 110-121 (for cluster-RCTs) and 123-147 (for other quasi-experimental studies), respectively. In order to identify RCTs, we will use the sensitivity-maximising version of the highly sensitive filter for RCTs recommended in the Cochrane Handbook.[24] For identification of cluster-RCTs, we will use the sensitivity-maximising filter for cluster-RCTs developed by Taljaard et al.[25] This filter was validated, among others, for a sample of cluster-RCTs in sub-Saharan Africa from before 2001 and showed good sensitivity (94%), with overall higher sensitivity for more recent studies. For identification of non-randomised studies that support causal inference of the relationship between exposure and outcome, we created an additional set of search terms pertaining to commonly used labels for quasi-experimental studies. We enhanced these search terms with the 'etiology' filter developed by the Hedges Group.[26] The methodological criteria used for developing the filter were found to be a good match for our inclusion criteria (including the use of a clearly identified comparison group, with examples given by the authors including "randomized controlled trials (RCT), quasi-randomized controlled trials, non-randomized controlled trials, cohort studies with case-by-case matching or statistical adjustment to create comparable groups, or nested case-control studies" [26]).

Finally, rows 149-157 of Table 2 show the exemplary search terms for LMICs, based on a filter for LMICs that is available from the Cochrane EPOC website (<http://epoc.cochrane.org/lmic-filters>). The search terms were expanded and updated to reflect the list of LMICs from 2008-2018.

Filters for LMICs and study designs were tested in MEDLINE for a sample of 10 studies (6 selected for being conducted in LMICs,[27-32] 4 selected for using quasi-experimental study designs [33-36]). The sensitivity of the search strategy for this sample was 100% (10/10 studies) for searches with study design filters, and 100% (6/6 studies) when adding the LMIC filter.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TABLE 2: EXEMPLARY SEARCH TERMS (MEDLINE VIA OVID)

Search #	Terms used	No. of hits
1	Exp Dementia/	148,649
2	Dement*.mp	114,488
3	Amentia*.mp	102
4	(major adj3 cognit* adj3 disorder*).mp	159
5	(alzheimer* or alzeimer* or (cortical adj4 sclerosis)).mp	140,775
6	((encephalopath* or cogniti* or neurocogniti*) adj4 (aids or acquired immun?deficiency syndrome or acquired immun? deficiency syndrome or hiv or human immun?deficiency virus or human immun? deficiency virus)).mp	3,302
7	"Pick Disease of the Brain"/	495
8	(Pick* disease).mp	3,308
9	(lobar adj3 atroph* adj3 brain).mp	10
10	Huntington Disease/	11,069
11	(Huntington* disease).mp	16,193
12	(Huntington* chorea).mp	1,349
13	Lewy Body Disease/	2,761
14	(Lewy bod* adj3 disease).mp	4,240
15	(cerebr* adj3 deteriorat*).mp	361
16	(cerebr* adj3 insufficien*).mp	2,079
17	((frontotemporal or fronto temporal or corticobasal or cortico basal or frontal lobe*) adj4 (degenerati* or dysfunction*)).mp	5,217
18	((cognit* or memory or cerebr*) adj3 (declin* or impair* or los* or deteriorat* or degenerat* or insufficen*)).mp	106,843
19	Cognitive Dysfunction/	8,749
20	(MCI or (mild adj2 cognit* impair*)).ti,ab.	20,332
21	Or/1-20	314,147
22	(Intervention* or therap* or treatment* or program* or manage* or prevent* or diagnos* or polic*).mp	12,485,776
23	exp Cognitive Therapy/	23,692
24	(cognit* adj3 therap*).mp	30,470
25	(cognit* psycho therap* or cognit* psychotherap*).mp.	119
26	(cognit* adj3 training).mp	3,571
27	(cognit* adj3 rehab*).mp	1,911

28	Or/23-27	36,923
29	exp Drug Therapy/	1,246,404
30	(Drug* or medicine* or pharmacotherap* or pharmaco* therap*).ti,ab.	1,838,638
31	exp Cholinesterase Inhibitors/	47,229
32	cholinesterase agent*.mp	30
33	cholinesterase inhibitor*.mp	21,340
34	exp Antipsychotic Agents/	115322
35	(Tranquili* adj3 (agent* or drug*)).mp	12,096
36	Antipsychotic*.mp	63916
37	(neuroleptic adj3 (agent* or drug*)).mp	3,296
38	exp Serotonin Uptake Inhibitors/	34,982
39	(serotonin uptake inhibitor* or serotonin reuptake inhibitor*).mp or ssri*.ti,ab	25,984
40	exp Benzodiazepines/	62,786
41	Benzodiazepine*.mp	42,836
42	exp "Hypnotics and Sedatives"/	115,358
43	(Sedative adj3 (effect* or agent*)).mp	5,467
44	(memantine or donepezil or rivastigmine or galantamine or souvenaid or risperidone or haloperidol or olanzapine or quetiapine or citalopram or dextromethorphan or carbamazepine or mirtazapine or sertraline or moclobemide or trazodone or melatonin or ramelteon or methylphenidate).mp	105,057
45	Or/29-44	3,080,487
46	exp Exercise Therapy/	42,856
47	Exercis*.mp	335,419
48	(Physical activit* or physical training).mp.	99,409
49	(Aerobic* or arobic*).mp	81,338
50	exp Exercise/	166,405
51	Or/46-50	497,630
52	(social adj3 activit*).mp	9,247
53	(social adj3 engag*).mp	2,774
54	(social adj3 stimul*).mp	2,178
55	Or/52-54	14,003
56	exp Psychotherapy/	180,508
57	(psycholog* therap* or psychotherap*).mp	85,389
58	((behavio?r* adj3 therap*) or (conditioning adj3 therap*)).mp	47,185
59	exp Counseling/	40,343

60	Counsel?ing.mp	89,908
61	psychosocial support systems/	145
62	((Psychosocial or psycho social) adj3 (support or interven* or care)).ti,ab	11,193
63	Or/56-62	315,606
64	exp Complementary Therapies/	208,840
65	((Alternative or compl?ment* or traditional) adj3 (medicine* or therap*)).mp	101,303
66	Acupunct*.mp	25,265
67	(herb* adj3 (tea or remedy or remedies or medicine*)).ti,ab.	16,075
68	Gingko.ti,ab	346
69	homeopath*.mp	6,178
70	((music or art or aroma or light or photo or pet or pets) adj3 therap*).ti,ab	16,656
71	Massage.ti,ab	9,025
72	(mind adj3 body).ti,ab	4,035
73	Phototherapy/	7,273
74	Or/64-73	302,897
75	exp Advance care planning/	8,277
76	(Advance? adj3 (care or medical or healthcare) adj3 plan*).mp	3,552
77	(decision* adj3 (aid* or support)).mp	41,646
78	Or/75-77	46,897
79	Case Management/	9,516
80	(communicati* adj3 skill* adj3 training).mp	1,283
81	(dementia care adj3 map*).mp	92
82	((person* or patient*) adj3 cent* adj3 care).mp	23,552
83	Or/79-82	34,244
84	("Resources for Enhancing Alzheimer's Caregiver Health" or "Strategies for Relatives").ti,ab.	88
85	Caregivers/ed [Education]	2,484
86	CAREGIVERS/px [Psychology]	18,509
87	Self-Help Groups/	8,626
88	exp Social support/	63,885
89	Or/84-88	87,559
90	Diagnosis, Computer-Assisted/	21,241
91	Telemedicine/	17,577
92	(Telemedicine or tele medicine).mp	21,573
93	exp Computers, Handheld/	5,107
94	((smart adj2 (phone* or device* or tablet*)) or smartphone*).mp	8,280

95	cognitive aid*.mp.	138
96	Reminder*.ti,ab	10,667
97	Robot*.mp	38,250
98	Or/90-97	102,392
99	22 or 28 or 45 or 51 or 55 or 63 or 74 or 78 or 83 or 89 or 98	13,800,589
100	21 and 99	208,431
101	randomized controlled trial.pt	462,693
102	controlled clinical trial.pt	92,457
103	(randomized or randomised).ab	495,756
104	Placebo.ab	189,758
105	drug therapy.fs	2,024,910
106	Randomly.ab	292,598
107	Trial.ab	431,012
108	Groups.ab	1,806,682
109	Or/101-108	4,294,404
110	randomized controlled trial.pt	462,693
111	(Cluster* adj2 randomi*).tw	9,224
112	((communit* adj2 intervention*) OR (communit* adj2 randomi*)).tw	6,858
113	Group* randomi*.tw	2,846
114	Or/111-113	18,443
115	intervention?.tw	782,326
116	cluster analysis/	56,328
117	health promotion/	66,499
118	program evaluation/	56,711
119	health education/	57,721
120	Or/115-119	965,052
121	114 or 120	968,364
122	110 or 121	1,366,397
123	risk.mp.	2,178,921
124	exp cohort studies/	1,751,258
125	between group.tw	21,162
126	Or/123-125	3,451,482
127	(non random* or nonrandom*).mp	33,945
128	Non-Randomized Controlled Trials as Topic/	359
129	quasi.mp	41,169
130	(natural adj3 experiment).mp	1,724
131	instrumental variable*.mp	1,969

132	Cohort.mp	516,750
133	before-after.mp	4,519
134	(before adj2 after adj study).mp.	1,810
135	Controlled Before-After Studies/	329
136	(difference-in-difference* or diff-in-diff).mp	1,782
137	regression discontinuity.mp	223
138	Historically Controlled Study/	139
139	historical* control.mp	3,400
140	Interrupted Time Series Analysis/	435
141	Interrupted Time Series.mp	2,280
142	Case-control.mp	287,943
143	Case-Control Studies/	249,334
144	Match*.mp	419,961
145	Propensity.mp	47,848
146	Propensity Score/	5,596
147	Or/127-146	1,205,777
148	126 or 147	4,094,244
149	Developing Countries.sh,kf.	81,106
150	(Africa or Asia or Caribbean or West Indies or South America or Latin America or Central America).hw,kf,ti,ab,cp.	242,209
151	(Afghan* or Albania* or Algeria* or Angola* or Anguilla* or Antigua* or Barbuda* or Argentina* or Armenia* or Azerbaijan* or Azeri or Bangladesh* or Barbados* or Benin* or Belarus* or Byelorussian or Belarus* or Belorussia* or Belize* or Bhutan* or Bolivia* or Bosnia* or Herzegovin* or Hercegovin* or Botswana or Botsuana or Motswana or Batswana or Brasil* or Brazil* or Burkina Faso or Burkina Fasso or Burkina* or Burundi* or Urundi* or Cambodia* or Cameroon* or Cameron* or Cape Verd* or Cabo Verde or Central African Republic or Chad* or Tchad* or Chile* or China or Chinese or Colombia* or Columbia* or Comoros or Comoro Islands or Comores or Comoran or Mayotte or Congo* or Costa Rica* or Cote d'Ivoire or Ivory Coast or Ivorian* or Cook Islands or Cuba* or Croat* or Djibouti* or Dominica* or East Timor or East Timur or Timor Leste or Timorese or Ecuador* or Equador* or Egypt* or El Salvador or Salvadoran or Eritrea* or Ethiopia* or Fiji* or Gabon* or Gambia* or Gaza or Georgia Republic or Georgian or Abkhazia* or Abchasia* or South Ossetia* or Ghana* or Grenada or Grenadian or Guatemala* or Guinea* or Guinea Bissau or Guian* or Guyana or Haiti* or Hondura* or India or Indian or Indonesia*	2,805,600

	or Iran* or Iraq* or Jamaica* or Jordan* or Kazakhstan* or Kazakh or Kenya* or Kiribati or Korea* or Kosovo or Kosova* or Kyrgyzstan or Kirghizia or Kyrgyz or Kirghiz or Kirgizstan or Lao PDR or Laos or Laotian or Lebanon or Lebanese or Lesotho or Mosotho or Basotho or Liberia* or Libya* or Macedonia* or FYROM or Madagasca* or Malagasy or Malaysia* or Malaya* or Malay or Sabah or Sarawak or Malawi* or Maldives or Maldivan or Mali or Malian or Marshall Islands or Marshallese or Mauritania* or Mauriti* or Agalega Islands or Mexico or Mexican or Micronesia* or Middle East* or Moldova* or Moldovia* or Transnistria* or Mongolia* or Montenegri* or Montserrat* or Morocco* or Mozambique or Mozambican or Myanmar* or Myanma or Burma or Burmese or Namibia* or Nauru* or Niue or Nepal* or Nicaragua* or Niger or Nigerien or Nigeria* or Oman* or Pakistan* or Palau* or Palestine or Palestinian or Panama or Panamanian or Paraguay* or Papua New Guinea* or Peru or Peruvian or Philippines or Philipines or Phillipines or Phillippines or Filipino or Philipino or Philippino or Phillipino or Phillippino or Rwanda* or Ruanda* or Saint Helen* or St Helen* or Saint Kitts or St Kitts or Kittian or Nevis* or Saint Lucia* or St Lucia* or Saint Vincent or St Vincent or Vicentian or Grenadines or Samoa* or Sao Tome* or Senegal* or Serbia* or Seychell* or Sierra Leone* or Sri Lanka* or Ceylon or Solomon Island* or Somali* or South Africa* or Sudan or Sudanese or Surinam* or Swaziland or Swazi or Eswatini or Syria or Syrian or Tajikistan or Tadjhikistan or Tadjikistan or Tajik or Tadjhik or Tanzania* or Thailand or Thai or Togo or Togolese or Tonga* or Tunisia* or Tokelau or Trinidad* or Tobago* or Turkey or Turkish or Turks or Turkmenistan or Turkmen or Tuvalu* or Uganda* or Ukraine or Ukrainian or Uruguay* or Uzbekistan* or Uzbek or Vanuatu or Venezuela* or Vietnam* or Viet Nam or Wallis Futuna or West Bank or Yemen* or Zambia* or Zimbabwe*).hw,kf,ti,ab,cp.	
152	((developing or less* developed or under developed or underdeveloped or middle income or low* income or underserved or under served or deprived or poor*) adj (countr* or nation? or population? or world)).ti,ab.	85,468
153	((developing or less* developed or under developed or underdeveloped or middle income or low* income) adj (economy or economies)).ti,ab.	440
154	(low* adj (gdp or gnp or gross domestic or gross national)).ti,ab.	217
155	(low adj3 middle adj3 countr*).ti,ab.	11,181
156	(lmic or lmics or third world or lami countr*).ti,ab.	5,792
157	transitional countr*.ti,ab.	146

158	Or/149-157	2,945,907
159	100 and (109 or 122 or 148) and 158	8,278
160	limit 159 to (comment or editorial or letter)	74
161	159 not 160	8,204
162	limit 161 to yr="2008 -Current"	6,322
163	exp animals/ not humans.sh.	4,496,553
164	162 not 163	5,786

Study selection

Search results from the database searches will be exported to a bibliographic reference manager and deduplicated. Two researchers will independently screen articles at the title and abstract level for eligibility. Full text for articles deemed eligible at this stage will be retrieved, including articles where no abstract was available at the first screening. Articles describing the same study will be linked together. Full-text articles will be independently assessed for inclusion eligibility by two researchers. Deviating decisions on inclusion will be resolved by discussion and consensus between the two researchers. If no consensus is reached by the two researchers, we will consult with a third researcher for a final decision on inclusion. We will record rates of agreement between researchers independently screening abstracts and full texts to measure the extent of disagreement using the kappa statistic. We will take a kappa of >0.8 as indication of ‘very good’ agreement.[37]

Inclusion and exclusion of studies at each stage will be illustrated with a PRISMA flow chart.[38] A list of included and excluded studies (with primary exclusion reason) will be made available.

Data extraction

Two researchers will independently extract the information listed in Box 3 from included studies. Selection of data to be extracted was informed by the review question and by practical insights regarding data extraction and synthesis from non-randomised studies.[39,40] We will contact authors of included abstracts to obtain full details of their studies if the information is not available from abstracts.

BOX 3: DATA TO BE EXTRACTED FROM INCLUDED STUDIES

- Publication details.
- Source of funding for the study.
- Geographical location.
- Care setting.
- Study design: description and coding of the study design and how causality of a treatment effect was supported, including which covariates were used in the analysis to control for confounding and judgement about whether criteria for causality for the specific study design were met (in the case of non-randomised studies).
- Participant details, including type of dementia and representativeness of local/regional/national population with dementia.
- Intervention: brief description of the intervention in terms of its aims, implementation and intervention details, including e.g. duration and intensity of the intervention, dosage of drugs, existence of a protocol or manual for psychosocial, training or education interventions, and other details that allow an informed judgement about the comparability of interventions within the same type of treatment.
- Comparator: description of the comparison group and the intervention received by them (if any), including a note on statistically significant differences in baseline characteristics between experimental and control groups.
- Outcomes: primary and secondary outcomes of the study, including information on how they were measured (instruments used).
- Results: effect size and measure of its variance for the primary outcome and for any other outcomes mentioned in the abstract or executive summary of the study. Preference will be given to adjusted effect sizes (i.e. taking into account covariates that might not be balanced across experimental and control group), and in cases where several adjusted results are presented we will extract the one where selection bias is best controlled (either through design or analysis, e.g., inclusion of most relevant confounding variables).
- Risk of bias information.

Risk of bias

We will assess the internal validity of included studies using appropriate tools. For RCTs, we will use the Cochrane Collaboration's recently updated risk of bias tool (RoB 2.0).[41]

1
2
3 We will use the Cochrane Collaboration’s ROBINS-I tool to assess risk of bias in non-
4 randomised studies.[42]

5
6
7
8 **Data synthesis**
9

10 We will first describe the interventions that have been evaluated in rigorous study designs in
11 LMICs and summarise the features of the intervention, where they were studied,
12 characteristics of the studies, and their findings. We are planning to tabulate interventions
13 according to who they are targeted at (person living with dementia, their carers, care
14 professionals and care systems), aim of the intervention (secondary prevention, treatment,
15 disease management, coping with the disease and caring for people living with dementia,
16 managing the impact of dementia on the care system), intervention type (including, but not
17 limited to, pharmaceuticals, cognitive therapy, technological interventions, exercise, training,
18 diagnosis, organisation of care, financing of care, policy interventions), and outcomes studied.
19 We plan to review details extracted from included studies on the population, intervention,
20 and outcomes (see Box 3) to group studies accordingly. For example, in terms of population,
21 included studies may be grouped according to severity of impairment (for people living with
22 dementia) and type of carer (unpaid, paid, professional, family caregiver). Tabulation along
23 this dimension will allow us to explore which types of interventions were shown to be effective
24 for each of the groups in order to provide sufficiently granular findings to inform decision-
25 making in specific contexts. Similarly, we plan to tabulate studies according to the aim of the
26 intervention, intervention type, and outcome studied, thereby providing a summary of the
27 evidence for different aspects of dementia interventions.
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Potentially relevant outcomes for this systematic review can be characterised by their type and
43 the stakeholder group they refer to. A draft list of potentially relevant outcomes and their
44 stakeholder groups according to which our analysis can be structured is provided in the online
45 supplementary table. The list is subject to change after reviewing the outcomes used in
46 included studies, which might use other outcomes that could necessitate a different
47 categorisation.
48
49
50
51
52

53 We will use the GRADE approach to rate the quality of evidence for each intervention.[43]
54
55
56
57
58
59
60

Quantitative synthesis

We will explore the feasibility of conducting quantitative synthesis of treatment effects through traditional pair-wise and network meta-analysis. Feasibility of quantitative synthesis will be assessed for each intervention studied in our sample of included studies. We will assess the similarity of the specific intervention in each study with other candidate interventions for a meta-analysis, the participants in the studies where this intervention was evaluated, and whether the same outcome was used. Quantitative synthesis can only be conducted for studies reporting the same outcome, although individual studies may use different instruments to measure this (e.g. the MMSE and ADAS-cog for cognition, and the Texas Functional Living Scale and Barthel scale for activities of daily living).

We will assess the feasibility to conduct both traditional pairwise and network meta-analysis. Pooled estimates are calculated as weighted averages of the treatment effects in included studies, where weights are assigned to each study based on its precision.[44] Network meta-analysis extends pairwise meta-analysis by incorporating both direct evidence about the relative effectiveness of interventions that have been compared to each other in a primary study and indirect evidence about the relative effectiveness of interventions that were never directly compared to each other, but are connected through a network of other interventions for which direct comparisons exist. In addition, network meta-analysis can be a valuable tool in delineating the effects of individual components of complex interventions, as recently shown in a network meta-analysis of multi-component interventions for dementia caregiver depression.[45] The validity of treatment effect estimates obtained through network meta-analysis depends on the similarity of the various direct comparisons in the network with respect to relevant treatment effect modifiers (e.g. severity of disease; age of participants; risk of bias due to study design and implementation) and consistency of treatment effects obtained from direct and indirect comparisons.[46]

It is anticipated that in our sample of included studies, there will be underlying differences between individual studies of the same intervention, in particular with respect to the details of the intervention and the setting. For example, a training intervention in one study is unlikely to be exactly the same intervention as in another study, even if a protocol is used to standardise the intervention, because, for example, the individual delivering the training changes. Such differences do not preclude pooling study results, but the heterogeneity in treatment effects resulting from underlying differences needs to be taken into account when

assigning weights to studies for a pooled estimate. Our default will therefore be to use a random-effects model, which takes into account between-study variation and assumes that included studies come from different populations, with unique details of the intervention and conditions of the study. The true treatment effect can therefore vary from study to study.[47]

Subgroup analysis

While a random-effects model takes into account between-study variation, it does not explain heterogeneity. We will aim to use subgroup analysis and meta-regression to identify any study-level characteristics that might explain variation in treatment effects. Potential candidate covariates for subgroup analysis and meta-regression are study design and quality (within RCTs: risk of bias; within non-RCTs: analytical method employed, e.g. instrumental variable, risk of bias), intervention details (e.g. drug dose; intensity of training; intensity of stimulation therapy), and setting (by country; by bracket of gross national income; by rural vs. urban setting). However, subgroup analysis will only produce meaningful insights when enough studies are included in each subgroup to detect any difference by the selected covariate (as opposed to a chance finding) and meta-regression should not be conducted for samples of less than 10 studies.[48] Given that we do not expect to identify a large number of robust dementia intervention studies in LMICs, it is unlikely that there will be sufficient studies of a given intervention with a specific outcome to allow meaningful subgroup analysis and meta-regression.

In cases where interventions were evaluated both by RCTs and non-randomised studies, we will obtain separate pooled effects for the two study types.[18] We will extract information on study design characteristics that will allow us to examine these as potential sources of heterogeneity.[39]

Exploring meta-bias

For each intervention-outcome pair, we will first assess in a funnel plot whether asymmetry exists with respect to expected random variation of treatment effects around the pooled effect estimate with decreasing study precision. Funnel plots are used to detect possibly ‘missing’ smaller studies with larger or smaller treatment effects than what would be expected by chance alone, for which publication bias is one possible explanation.[49] We will then use contour-enhanced funnel plots to assess whether any observed asymmetry is likely due to publication bias favouring the publication of statistically significant results.[50]

We anticipate identifying only a small number of studies eligible for inclusion in our quantitative review (meeting the criteria of being conducted in a LMIC and using a robust study design). In a scenario where not more than one LMIC study exists for any combination of intervention and outcome, pairwise meta-analysis will become impossible. For network meta-analysis, the existence of only a handful of LMIC studies, even if a common comparator (e.g., standard care) exists, makes it difficult to assess whether the assumptions of similarity (with respect to treatment effect modifiers) and consistency (agreement between direct and indirect estimates of treatment effect) hold. In case of a lack of eligible studies meeting our primary inclusion criteria, we will use our secondary set of inclusion criteria for studies using less robust research designs and will explore the feasibility of quantitative synthesis of these.

Given the reliance of past efforts to develop recommendations for dementia interventions in LMICs on evidence from high-income countries,^[7,15] our primary aim is to advance our understanding of what works in LMICs and provide policy-makers, people living with dementia and their carers, health and care professionals and others with evidence that is of immediate relevance to their setting. However, should quantitative synthesis of LMIC studies not be feasible due to a lack of studies reporting the same outcome, we will pursue an alternative way of obtaining pooled estimates of the comparative effectiveness of dementia interventions relevant for LMICs, as outlined below. In a scenario where we are unable to identify enough primary studies of dementia interventions in LMICs, we will quantitatively synthesise available evidence from methodologically robust studies from high-income countries, as identified in the MODEM toolkit (www.modem-dementia.org.uk). We will discuss existing interventions with dementia experts from the STRiDE partner countries to identify those that have the highest relevance for LMICs. We will then extract relevant information from studies meeting our study design inclusion criteria in the MODEM data base and obtain pooled estimates for the effectiveness and comparative effectiveness of these interventions. We will develop a separate protocol for this approach should it become necessary (i.e. in the case of not identifying eligible studies in LMICs).

Patient and public involvement

While no people living with dementia or carers were involved in the development of this protocol, the research project under which this systematic review will be undertaken (STRiDE), was developed in close collaboration with dementia advocacy groups and experts by

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

experience. People living with dementia and carers will be involved in later stages of the systematic review process (selection of relevant interventions for wider dissemination as described below).

ETHICS AND DISSEMINATION

No primary data collection will be conducted. We will include published reports of studies and will synthesise results of these at the aggregate level. We therefore did not seek ethics approval.

We plan to publish the findings of this systematic review both as a peer-reviewed article and in formats more accessible to people living with dementia, their carers, policy-makers, care professionals, and lay audiences, including on a website and DVD and in brief evidence summaries.

COMPETING INTERESTS

The authors declare no competing interests.

FUNDING

This work is conducted as part of the "Strengthening responses to dementia in developing countries" (STRiDE) project, supported by the UK Research and Innovation's Global Challenges Research Fund (ES/P010938/1). The funder was not involved in the development of this protocol at any stage.

AUTHORS' CONTRIBUTIONS

ACH, DMD, HN and MSK defined the scope of the review and review question. DMD, HN and MSK developed inclusion/exclusion criteria. AF consulted on the databases to be searched and search terms used. MSK drafted the protocol. MSK, HN, DMD, SA, DO, AF, SH, MK, CM, DN, MLO, and ACH reviewed the draft protocol along with the search strategy and contributed to a revised version. MSK acts as the guarantor of the manuscript.

REFERENCES

- 1 Prince M, Wimo A, Guerchet M, *et al.* World Alzheimer Report 2015: The Global Impact of Dementia. London: 2015.
<https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf> (accessed 21 May 2018).
- 2 Alzheimer's Association. What Is Dementia? 2018.<https://www.alz.org/what-is-dementia.asp> (accessed 25 Jun 2018).
- 3 Patel V. Mental health in low- and middle-income countries. *Br Med Bull* 2007;**81–82**:81–96. doi:10.1093/bmb/ldmo10
- 4 Livingston G, Sommerlad A, Orgeta V, *et al.* Dementia prevention, intervention, and care. *Lancet* 2017;**390**:2673–734. doi:10.1016/S0140-6736(17)31363-6
- 5 World Health Organization. Global action plan on the public health response to dementia 2017–2025. Geneva: 2017.
<http://apps.who.int/iris/bitstream/handle/10665/259615/9789241513487-eng.pdf;jsessionid=991FCCD18EF2BA8839F7B6048A28757B?sequence=1> (accessed 29 May 2018).
- 6 Comas-Herrera A, Knapp M, Wittenberg R, *et al.* MODEM: A comprehensive approach to modelling outcome and costs impacts of interventions for dementia. Protocol paper. *BMC Health Serv Res* 2017;**17**:25. doi:10.1186/s12913-016-1945-x
- 7 Prince MJ, Comas-Herrera A, Knapp M, *et al.* World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future. London: : Alzheimer's Disease International (ADI) 2016.
<http://eprints.lse.ac.uk/67858/> (accessed 21 May 2018).
- 8 Rubin DB. For objective causal inference, design trumps analysis. *Ann Appl Stat* 2008;**2**:808–40. doi:10.1214/08-AOAS187
- 9 Holland PW. Statistics and Causal Inference. *J Am Stat Assoc* 1986;**81**:945–60. doi:10.2307/2289064
- 10 Spector A, Thorgrimsen L, Woods B, *et al.* Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia. *Br J Psychiatry* 2003;**183**:248–54. doi:10.1192/bjp.183.3.248
- 11 Aguirre E, Hoare Z, Streeter A, *et al.* Cognitive stimulation therapy (CST) for people with dementia-who benefits most? *Int J Geriatr Psychiatry* 2013;**28**:284–90. doi:10.1002/gps.3823
- 12 Molloy DW, Guyatt GH, Russo R, *et al.* Systematic Implementation of an Advance Directive Program in Nursing Homes. *JAMA* 2000;**283**:1437. doi:10.1001/jama.283.11.1437
- 13 Teri L, Huda P, Gibbons L, *et al.* STAR: A Dementia-Specific Training Program for Staff in Assisted Living Residences. *Gerontologist* 2005;**45**:686–93. doi:10.1093/geront/45.5.686
- 14 Livingston G, Barber J, Rapaport P, *et al.* Clinical effectiveness of a manual based coping strategy programme (START, STRategies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial. *BMJ* 2013;**347**:f6276. doi:10.1136/BMJ.F6276
- 15 Prince MJ, Acosta D, Castro-Costa E, *et al.* Packages of care for dementia in low- and

- middle-income countries. *PLoS Med* 2009;**6**:e1000176. <http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000176> <https://www.cabdirect.org/cabdirect/abstract/20103000951>
- 16 Shamseer L, Moher D, Clarke M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;**350**:g7647. doi:10.1136/BMJ.G7647
 - 17 Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. *Acta Psychiatr Scand* 2009;**119**:252–65. doi:10.1111/j.1600-0447.2008.01326.x
 - 18 Reeves BC, Deeks JJ, Higgins JPT, *et al.* Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.* The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
 - 19 World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. Geneva: 2012. http://apps.who.int/iris/bitstream/handle/10665/75263/9789241564458_eng.pdf?sequence=1 (accessed 29 May 2018).
 - 20 O'Connor D, Green S, Higgins JPT. Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0.* The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
 - 21 Prince MJ, Acosta D, Castro-Costa E, *et al.* Packages of care for dementia in low- and middle-income countries. *PLoS Med* 2009;**6**:e1000176. doi:10.1371/journal.pmed.1000176
 - 22 Cochrane Effective Practice and Organisation of Care (EPOC). What study designs can be considered for inclusion in an EPOC review and what should they be called? EPOC Resources for review authors. 2017.
 - 23 Reeves BC, Wells GA, Waddington H. Quasi-experimental study designs series—paper 5: a checklist for classifying studies evaluating the effects on health interventions—a taxonomy without labels. *J Clin Epidemiol* 2017;**89**:30–42. doi:10.1016/J.JCLINEPI.2017.02.016
 - 24 Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S., eds. *Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.* The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
 - 25 Taljaard M, McGowan J, Grimshaw JM, *et al.* Electronic search strategies to identify reports of cluster randomized trials in MEDLINE: low precision will improve with adherence to reporting standards. *BMC Med Res Methodol* 2010;**10**:15. doi:10.1186/1471-2288-10-15
 - 26 Wilczynski NL, McKibbin KA, Walter SD, *et al.* MEDLINE clinical queries are robust when searching in recent publishing years. *J Am Med Informatics Assoc* 2013;**20**:363–8. doi:10.1136/amiajnl-2012-001075
 - 27 Dias A, Dewey ME, D'Souza J, *et al.* The effectiveness of a home care program for supporting caregivers of persons with dementia in developing countries: a randomised controlled trial from Goa, India. *PLoS One* 2008;**3**:e2333. doi:10.1371/journal.pone.0002333

- 28 Menezes AV, Aguiar A da S de, Alves EF, *et al.* [Effectiveness of a cognitive-motorphysiotherapeutical therapy intervention in institutionalized older adults with mild cognitive impairment and mild dementia]. *Cien Saude Colet* 2016;**21**:3459–67. doi:10.1590/1413-812320152111.17892015
- 29 Caramelli P, Laks J, Palmini ALF, *et al.* Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). *Arq Neuropsiquiatr* 2014;**72**:411–7. <http://www.ncbi.nlm.nih.gov/pubmed/24964105> (accessed 15 Aug 2018).
- 30 Guerra M, Ferri CP, Fonseca M, *et al.* Helping carers to care: the 10/66 dementia research group's randomized control trial of a caregiver intervention in Peru. *Rev Bras Psiquiatr* 2011;**33**:47–54. <http://www.ncbi.nlm.nih.gov/pubmed/20602013> (accessed 15 Aug 2018).
- 31 Lam LC-W, Chan WC, Leung T, *et al.* Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial. *PLoS One* 2015;**10**:e0118173. doi:10.1371/journal.pone.0118173
- 32 Liu P, Kong M, Liu S, *et al.* Effect of reinforcing kidney-essence, removing phlegm, and promoting mental therapy on treating Alzheimer's disease. *J Tradit Chinese Med = Chung i tsa chih ying wen pan* 2013;**33**:449–54. <http://www.ncbi.nlm.nih.gov/pubmed/24187864> (accessed 15 Aug 2018).
- 33 Chang F-Y, Huang H-C, Lin K-C, *et al.* The effect of a music programme during lunchtime on the problem behaviour of the older residents with dementia at an institution in Taiwan. *J Clin Nurs* 2010;**19**:939–48. doi:10.1111/j.1365-2702.2009.02801.x
- 34 Tate JA, Snitz BE, Alvarez KA, *et al.* Infection hospitalization increases risk of dementia in the elderly. *Crit Care Med* 2014;**42**:1037–46. doi:10.1097/CCM.0000000000000123
- 35 Franco C, Sola M del M, Justo E. [Reducing psychological discomfort and overload in Alzheimer's family caregivers through a mindfulness meditation program]. *Rev Esp Geriatr Gerontol* 2010;**45**:252–8. doi:10.1016/j.regg.2010.03.006
- 36 Buettner LL, Fitzsimmons S. Promoting health in early-stage dementia: evaluation of a 12-week course. *J Gerontol Nurs* 2009;**35**:39–49. <http://www.ncbi.nlm.nih.gov/pubmed/19326828> (accessed 15 Aug 2018).
- 37 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;**33**:159–74. <http://www.ncbi.nlm.nih.gov/pubmed/843571> (accessed 25 Jun 2018).
- 38 Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;**6**:e1000097. doi:10.1371/journal.pmed.1000097
- 39 Becker BJ, Aloe AM, Duvendack M, *et al.* Quasi-experimental study designs series—paper 10: synthesizing evidence for effects collected from quasi-experimental studies presents surmountable challenges. *J Clin Epidemiol* 2017;**89**:84–91. doi:10.1016/J.JCLINEPI.2017.02.014
- 40 Aloe AM, Becker BJ, Duvendack M, *et al.* Quasi-experimental study designs series—paper 9: collecting data from quasi-experimental studies. *J Clin Epidemiol* 2017;**89**:77–83.

- doi:10.1016/J.JCLINEPI.2017.02.013
- 41 Higgins JP, Sterne JA, Savovic J, *et al.* A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (editors). *Cochrane Methods. Cochrane Database Syst Rev* 2016;**10** (suppl. doi:dx.doi.org/10.1002/14651858.CD201601
 - 42 Sterne JA, Hernán MA, Reeves BC, *et al.* ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016;**355**:i4919. doi:10.1136/bmj.i4919
 - 43 Schuenemann H, Brozek J, Guyatt G, *et al.* *Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach.* 2013. <https://gdt.gradepro.org/app/handbook/handbook.html> (accessed 7 Nov 2018).
 - 44 Lau J, Ioannidis JPA, Schmid CH, *et al.* Quantitative Synthesis in Systematic Reviews. *Ann Intern Med* 1997;**127**:820–6. <http://annals.org/article.aspx?articleid=710939>
 - 45 Liew TM, Lee CS. Reappraising the Efficacy and Acceptability of Multicomponent Interventions for Caregiver Depression in Dementia: The Utility of Network Meta-Analysis. *Gerontologist* Published Online First: 31 May 2018. doi:10.1093/geront/gny061
 - 46 Cipriani A, Higgins JPT, Geddes JR, *et al.* Conceptual and Technical Challenges in Network Meta-analysis. *Ann Intern Med* 2013;**159**:130. doi:10.7326/0003-4819-159-2-201307160-00008
 - 47 Borenstein M, Hedges L V., Higgins JPT, *et al.* A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods* 2010;**1**:97–111. doi:10.1002/jrsm.12
 - 48 Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.* The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
 - 49 Sterne JAC, Sutton AJ, Ioannidis JPA, *et al.* Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;**343**:d4002. doi:10.1136/BMJ.D4002
 - 50 Peters JL, Sutton AJ, Jones DR, *et al.* Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. *J Clin Epidemiol* 2008;**61**:991–6. doi:10.1016/j.jclinepi.2007.11.010

Online supplementary material

Effectiveness of interventions for dementia in low- and middle-income countries: Protocol for a systematic review, pairwise and network meta-analysis

Maximilian Salcher-Konrad, Huseyin Naci, David McDaid, Suvarna Alladi, Déborah Oliveira, Andra Fry, Shereen Hussein, Martin Knapp, Christine Musyim, David M. Ndeti, Mariana Lopez-Ortega, Adelina Comas-Herrera

For peer review only

Supplementary table: Draft outcome categories

Types of outcomes	Outcomes relevant for:		
	Person living with dementia	Carer	Care system/society
Diagnosis	X		X
Clinical outcomes			
- Cognition	X		
- Depression and anxiety	X		
- Behaviour	X		
- Physical health	X		
Quality of life and functioning			
- Quality of life of person with dementia	X		
- Activities of daily living/IADL	X		
- Social and role functioning	X		
Carer outcomes			
- Quality of life of carer		X	
- Carer burden		X	
- Mental health of carer		X	
- Carer economic outcomes		X	
- Carer professional development		X	
- Carer retention		X	
Care provided			
- Satisfaction with care	X	X	X
- Care setting (institutionalisation)	X		
- Appropriateness and quality of care (e.g. use of feeding tubes)	X		X
Economic outcomes			
- Service use and cost reductions			X
- Out-of-pocket payments	X	X	
- Opportunity costs	X	X	X
End-of-life			
- Place of death	X		
- Decision-making	X		

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on page #
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2, 5
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	27
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	26
Sponsor	5b	Provide name for the review funder and/or sponsor	26
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	26
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6-11
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	11-13
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits such that it could be	14-20

		repeated	
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	21
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	21
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, duplicate), any processes for obtaining and confirming data from investigators	21
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	22
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7-8, Online Supplement
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	22-23
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	23
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ)	23-25
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	24-25
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	23
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	25
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	23

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.